CN113666968A - Organic electroluminescent material and device - Google Patents

Organic electroluminescent material and device Download PDF

Info

Publication number
CN113666968A
CN113666968A CN202110529720.7A CN202110529720A CN113666968A CN 113666968 A CN113666968 A CN 113666968A CN 202110529720 A CN202110529720 A CN 202110529720A CN 113666968 A CN113666968 A CN 113666968A
Authority
CN
China
Prior art keywords
group
compound
ring
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110529720.7A
Other languages
Chinese (zh)
Inventor
亚力克西·鲍里索维奇·迪亚特金
格扎·西盖蒂
蔡瑞益
皮埃尔-吕克·T·布德罗
约瑟夫·A·马克尔
内尔·帕尔默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universal Display Corp
Original Assignee
Universal Display Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/316,895 external-priority patent/US20210380617A1/en
Application filed by Universal Display Corp filed Critical Universal Display Corp
Publication of CN113666968A publication Critical patent/CN113666968A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0033Iridium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086Platinum compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • H10K50/12OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising dopants
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K71/00Manufacture or treatment specially adapted for the organic devices covered by this subclass
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30Coordination compounds
    • H10K85/321Metal complexes comprising a group IIIA element, e.g. Tris (8-hydroxyquinoline) gallium [Gaq3]
    • H10K85/322Metal complexes comprising a group IIIA element, e.g. Tris (8-hydroxyquinoline) gallium [Gaq3] comprising boron
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30Coordination compounds
    • H10K85/341Transition metal complexes, e.g. Ru(II)polypyridine complexes
    • H10K85/342Transition metal complexes, e.g. Ru(II)polypyridine complexes comprising iridium
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30Coordination compounds
    • H10K85/341Transition metal complexes, e.g. Ru(II)polypyridine complexes
    • H10K85/346Transition metal complexes, e.g. Ru(II)polypyridine complexes comprising platinum
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30Coordination compounds
    • H10K85/361Polynuclear complexes, i.e. complexes comprising two or more metal centers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/40Organosilicon compounds, e.g. TIPS pentacene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/622Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing four rings, e.g. pyrene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/624Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing six or more rings
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/626Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing more than one polycyclic condensed aromatic rings, e.g. bis-anthracene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/631Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine
    • H10K85/633Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine comprising polycyclic condensed aromatic hydrocarbons as substituents on the nitrogen atom
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/654Aromatic compounds comprising a hetero atom comprising only nitrogen as heteroatom
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6572Polycyclic condensed heteroaromatic hydrocarbons comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6574Polycyclic condensed heteroaromatic hydrocarbons comprising only oxygen in the heteroaromatic polycondensed ring system, e.g. cumarine dyes
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6576Polycyclic condensed heteroaromatic hydrocarbons comprising only sulfur in the heteroaromatic polycondensed ring system, e.g. benzothiophene
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1044Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1059Heterocyclic compounds characterised by ligands containing three nitrogen atoms as heteroatoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1059Heterocyclic compounds characterised by ligands containing three nitrogen atoms as heteroatoms
    • C09K2211/107Heterocyclic compounds characterised by ligands containing three nitrogen atoms as heteroatoms with other heteroatoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/18Metal complexes
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/18Metal complexes
    • C09K2211/185Metal complexes of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd

Abstract

The present application relates to organic electroluminescent materials and devices. Disclosed is a chemical combinationAn article comprising formula I
Figure DDA0003067090960000011
Ligand L ofA

Description

Organic electroluminescent material and device
CROSS-REFERENCE TO RELATED APPLICATIONS
Priority of united states provisional application No. 63/024,566 filed on day 5, 14, 2020 and 63/155,914 filed on day 3, 2021, is claimed in this application, the entire contents of which are incorporated herein by reference.
Technical Field
The present disclosure relates generally to organometallic compounds and formulations and various uses thereof, including as emitters in devices such as organic light emitting diodes and related electronic devices.
Background
Photovoltaic devices utilizing organic materials are becoming increasingly popular for a variety of reasons. Many of the materials used to make such devices are relatively inexpensive, and therefore organic photovoltaic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials (e.g., their flexibility) may make them more suitable for particular applications, such as fabrication on flexible substrates. Examples of organic optoelectronic devices include organic light emitting diodes/devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, organic materials may have performance advantages over conventional materials.
OLEDs utilize organic thin films that emit light when a voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for applications such as flat panel displays, lighting and backlighting.
One application of phosphorescent emissive molecules is in full color displays. Industry standards for such displays require pixels adapted to emit a particular color, known as a "saturated" color. In particular, these standards require saturated red, green, and blue pixels. Alternatively, OLEDs can be designed to emit white light. In conventional liquid crystal displays, an absorptive filter is used to filter the emission from a white backlight to produce red, green, and blue emissions. The same technique can also be used for OLEDs. The white OLED may be a single emission layer (EML) device or a stacked structure. Color can be measured using CIE coordinates well known in the art.
Disclosure of Invention
In one aspect, the present disclosure provides a composition comprising formula I
Figure BDA0003067090940000021
Ligand L ofAThe compound of (1). In formula I:
Z1、Z2、Z3、Z4、Z5and Z6Each of which is independently C or N;
k is selected from the group consisting of: a direct bond, O and S;
when K is O or S, then Z6Is C;
each of ring a1 and ring a2 is independently a 5-or 6-membered carbocyclic or heterocyclic ring, or a polycyclic fused ring system comprising more than one 5-or 6-membered carbocyclic or heterocyclic ring;
RAand RBEach of which is independently mono-substituted, up to a maximum of allowed substitutions, or no substitution;
ligand LACoordinating to metal M by two indicated dashed lines;
m is selected from the group consisting of: ir, Os, Ru, Rh, Pt, Pd, Cu, Ag, Au, Be, Mg, Al, Ca, Ti, Mn, Co, Zn, Ga, Ge and Zr;
m is coordinated to at least one other ligand;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands;
L1is an organic linking group;
when M is selected from the group consisting of Ru, Os, and Ir, then K is O or S;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is a direct bond, then M forms at least one bond with oxygen or sulfur;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is O or S, then L1Selected from the group consisting of: -CR ═ N-, -CR ' R ' -, -NR ' BR-、-CR'R"O-、-CR'R"S-、-CR'=CR"O-、-CR'=CR"S-、-CR'=CR'NR-、-CR'=CR"CR2-, -C (═ N-) -, and-C (═ CR-) -, and formula II
Figure BDA0003067090940000022
The structure of (1); ring A3 is a 5-or 6-membered carbocyclic or heterocyclic ring, and contains Z7And Z8Together form a system of 18 pi electrons; z7And Z8Each of which is independently C or N;
each RA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; and is
Any two adjacent RA、RB、RCR, R' and R "may be joined or fused together to form a ring.
In another aspect, the present disclosure provides a formulation of a compound of the present disclosure.
In yet another aspect, the present disclosure provides an OLED having an organic layer comprising a compound of the present disclosure.
In yet another aspect, the present disclosure provides a consumer product comprising an OLED having an organic layer comprising a compound of the present disclosure.
Drawings
Fig. 1 shows an organic light emitting device.
Fig. 2 shows an inverted organic light emitting device without a separate electron transport layer.
FIG. 3 shows a complex Ir [ L ] of the present inventionA1-(33)(2)(1)(1)][LB148]2Photoluminescence spectrum of (a).
FIG. 4 shows a complex Ir [ L ] of the present inventionA1-(33)(2)(1)(1)][LB28]2Photoluminescence spectrum of (a).
FIG. 5 shows a complex Ir [ L ] of the present inventionA1-(33)(2)(1)(1)][LB540]2Photoluminescence spectrum of (a).
Detailed Description
A. Term(s) for
Unless otherwise specified, the following terms as used herein are defined as follows:
as used herein, the term "organic" includes polymeric materials and small molecule organic materials that may be used to fabricate organic optoelectronic devices. "Small molecule" refers to any organic material that is not a polymer, and "small molecules" may actually be quite large. In some cases, the small molecule may include a repeat unit. For example, the use of long chain alkyl groups as substituents does not remove a molecule from the "small molecule" class. Small molecules can also be incorporated into polymers, for example as pendant groups on the polymer backbone or as part of the backbone. Small molecules can also serve as the core moiety of a dendrimer, which consists of a series of chemical shells built on the core moiety. The core moiety of the dendrimer may be a fluorescent or phosphorescent small molecule emitter. Dendrimers can be "small molecules," and all dendrimers currently used in the OLED art are considered small molecules.
As used herein, "top" means furthest from the substrate, and "bottom" means closest to the substrate. Where a first layer is described as being "disposed" over "a second layer, the first layer is disposed farther from the substrate. Other layers may be present between the first and second layers, unless it is specified that the first layer is "in contact with" the second layer. For example, a cathode may be described as "disposed over" an anode even though various organic layers are present between the cathode and the anode.
As used herein, "solution processable" means capable of being dissolved, dispersed or transported in and/or deposited from a liquid medium in the form of a solution or suspension.
A ligand may be referred to as "photoactive" when it is believed that the ligand contributes directly to the photoactive properties of the emissive material. A ligand may be referred to as "ancillary" when it is believed that the ligand does not contribute to the photoactive properties of the emissive material, but the ancillary ligand may alter the properties of the photoactive ligand.
As used herein, and as will be generally understood by those skilled in the art, if the first energy level is closer to the vacuum energy level, the first "Highest Occupied Molecular Orbital" (HOMO) or "Lowest Unoccupied Molecular Orbital" (LUMO) energy level is "greater than" or "higher than" the second HOMO or LUMO energy level. Since Ionization Potential (IP) is measured as negative energy relative to vacuum level, a higher HOMO level corresponds to an IP with a smaller absolute value (less negative IP). Similarly, a higher LUMO energy level corresponds to an Electron Affinity (EA) with a smaller absolute value (a less negative EA). On a conventional energy level diagram with vacuum levels at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. The "higher" HOMO or LUMO energy level appears closer to the top of this figure than the "lower" HOMO or LUMO energy level.
As used herein, and as will be generally understood by those skilled in the art, a first work function is "greater than" or "higher than" a second work function if the first work function has a higher absolute value. Since the work function is typically measured as negative relative to the vacuum level, this means that the "higher" work function is more negative (more negative). On a conventional energy level diagram with vacuum level at the top, the "higher" work function is illustrated as being farther from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different rule than work functions.
The terms "halo," "halogen," and "halo" are used interchangeably and refer to fluorine, chlorine, bromine, and iodine.
The term "acyl" refers to a substituted carbonyl group (C (O) -Rs)。
The term "ester" refers to a substituted oxycarbonyl group (-O-C (O) -R)sor-C (O) -O-Rs) A group.
The term "ether" means-ORsA group.
The terms "thio" or "thioether" are used interchangeablyUsing and indicating-SRsA group.
The term "sulfinyl" refers to-S (O) -RsA group.
The term "sulfonyl" refers to-SO2-RsA group.
The term "phosphino" refers to-P (R)s)3Group, wherein each RsMay be the same or different.
The term "silyl" refers to-Si (R)s)3Group, wherein each RsMay be the same or different.
The term "oxyboronyl" refers to-B (R)s)2Group or Lewis adduct thereof (R) -B (R)s)3Group, wherein RsMay be the same or different.
In each of the above, RsMay be hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, and combinations thereof. Preferred RsSelected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The term "alkyl" refers to and includes straight and branched chain alkyl groups. Preferred alkyl groups are those containing from one to fifteen carbon atoms and include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, and the like. In addition, the alkyl group may be optionally substituted.
The term "cycloalkyl" refers to and includes monocyclic, polycyclic and spiroalkyl groups. Preferred cycloalkyl groups are those containing 3 to 12 ring carbon atoms and include cyclopropyl, cyclopentyl, cyclohexyl, bicyclo [3.1.1] heptyl, spiro [4.5] decyl, spiro [5.5] undecyl, adamantyl, and the like. In addition, the cycloalkyl group may be optionally substituted.
The term "heteroalkyl" or "heterocycloalkyl" refers to an alkyl or cycloalkyl group, respectively, having at least one carbon atom replaced with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. In addition, heteroalkyl or heterocycloalkyl groups may be optionally substituted.
The term "alkenyl" refers to and includes straight and branched chain alkenyl groups. An alkenyl group is essentially an alkyl group that includes at least one carbon-carbon double bond in the alkyl chain. Cycloalkenyl is essentially cycloalkyl that includes at least one carbon-carbon double bond in the cycloalkyl ring. The term "heteroalkenyl" as used herein refers to an alkenyl group having at least one carbon atom replaced with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. Preferred alkenyl, cycloalkenyl or heteroalkenyl groups are those containing from two to fifteen carbon atoms. In addition, the alkenyl, cycloalkenyl or heteroalkenyl groups may be optionally substituted.
The term "alkynyl" refers to and includes straight and branched chain alkynyl groups. Alkynyl is essentially an alkyl group comprising at least one carbon-carbon triple bond in the alkyl chain. Preferred alkynyl groups are those containing from two to fifteen carbon atoms. In addition, alkynyl groups may be optionally substituted.
The terms "aralkyl" or "arylalkyl" are used interchangeably and refer to an alkyl group substituted with an aryl group. In addition, the aralkyl group may be optionally substituted.
The term "heterocyclyl" refers to and includes both aromatic and non-aromatic cyclic groups containing at least one heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. Aromatic heterocyclic groups may be used interchangeably with heteroaryl groups. Preferred non-aromatic heterocyclic groups are heterocyclic groups containing 3 to 7 ring atoms including at least one heteroatom and include cyclic amines such as morpholinyl, piperidinyl, pyrrolidinyl and the like, and cyclic ethers/thioethers such as tetrahydrofuran, tetrahydropyran, tetrahydrothiophene and the like. In addition, the heterocyclic group may be optionally substituted.
The term "aryl" refers to and includes monocyclic aromatic hydrocarbon radicals and polycyclic aromatic ring systems. Polycyclic rings may have two contiguous rings of two carbons (the rings being "fused") Two or more rings in common, wherein at least one of the rings is an aromatic hydrocarbyl, for example the other rings may be cycloalkyl, cycloalkenyl, aryl, heterocyclic and/or heteroaryl. Preferred aryl groups are those containing from six to thirty carbon atoms, preferably from six to twenty carbon atoms, more preferably from six to twelve carbon atoms. Especially preferred are aryl groups having six carbons, ten carbons, or twelve carbons. Suitable aryl groups include phenyl, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, perylene,
Figure BDA0003067090940000061
Perylene and azulene, preferably phenyl, biphenyl, terphenyl, triphenylene, fluorene and naphthalene. In addition, the aryl group may be optionally substituted.
The term "heteroaryl" refers to and includes monocyclic aromatic groups and polycyclic aromatic ring systems that include at least one heteroatom. Heteroatoms include, but are not limited to O, S, N, P, B, Si and Se. In many cases O, S or N are preferred heteroatoms. Monocyclic heteroaromatic systems are preferably monocyclic with 5 or 6 ring atoms, and rings may have one to six heteroatoms. A heteropolycyclic system can have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused"), wherein at least one of the rings is heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryls, heterocycles and/or heteroaryls. The heterocyclic aromatic ring system may have one to six heteroatoms per ring of the polycyclic aromatic ring system. Preferred heteroaryl groups are those containing from three to thirty carbon atoms, preferably from three to twenty carbon atoms, more preferably from three to twelve carbon atoms. Suitable heteroaryl groups include dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzothienopyridine, and selenenopyridine, preferably dibenzothiophene, and benzothiophene, Dibenzofurans, dibenzoselenophenes, carbazoles, indolocarbazoles, imidazoles, pyridines, triazines, benzimidazoles, 1, 2-azaborines, 1, 3-azaborines, 1, 4-azaborines, borazines, and aza analogs thereof. In addition, the heteroaryl group may be optionally substituted.
Of the aryl and heteroaryl groups listed above, triphenylene, naphthalene, anthracene, dibenzothiophene, dibenzofuran, dibenzoselenophene, carbazole, indolocarbazole, imidazole, pyridine, pyrazine, pyrimidine, triazine, and benzimidazole are of particular interest, as well as their respective corresponding aza analogues.
The terms alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, heterocyclyl, aryl, and heteroaryl, as used herein, are independently unsubstituted or independently substituted with one or more general substituents.
In many cases, typical substituents are selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, borinyl, and combinations thereof.
In some cases, preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, oxyboronyl, and combinations thereof.
In some cases, more preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, aryl, heteroaryl, thio, and combinations thereof.
In other cases, most preferred general substituents are selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The terms "substituted" and "substitution" mean that a substituent other than H is bonded to the relevant position, e.g., carbon or nitrogen. For example, when R is1When representing a single substitution, then one R1Must not be H (i.e., substituted). Similarly, when R is1When representing disubstituted, then two R1Must not be H. Similarly, when R is1When represents zero or no substitution, R1For example, it may be hydrogen of available valency for the ring atoms, such as the carbon atom of benzene and the nitrogen atom of pyrrole, or it may be hydrogen of only zero for ring atoms having fully saturated valency, such as the nitrogen atom of pyridine. The maximum number of substitutions possible in a ring structure will depend on the total number of available valences in the ring atoms.
As used herein, "a combination thereof" means that one or more members of the applicable list are combined to form a known or chemically stable arrangement that one of ordinary skill in the art can envision from the applicable list. For example, alkyl and deuterium can be combined to form a partially or fully deuterated alkyl; halogen and alkyl may combine to form haloalkyl substituents; and halogen, alkyl, and aryl groups may be combined to form haloaralkyl groups. In one example, the term substituted includes combinations of two to four of the listed groups. In another example, the term substitution includes a combination of two to three groups. In yet another example, the term substitution includes a combination of two groups. Preferred combinations of substituents are those containing up to fifty atoms other than hydrogen or deuterium, or those containing up to forty atoms other than hydrogen or deuterium, or those containing up to thirty atoms other than hydrogen or deuterium. In many cases, a preferred combination of substituents will include up to twenty atoms that are not hydrogen or deuterium.
The term "aza" in the fragment described herein, i.e., aza-dibenzofuran, aza-dibenzothiophene, etc., means that one or more of the C-H groups in the corresponding aromatic ring can be replaced by a nitrogen atom, for example and without any limitation, azatriphenylene encompasses dibenzo [ f, H ] quinoxaline and dibenzo [ f, H ] quinoline. Other nitrogen analogs of the aza-derivatives described above can be readily envisioned by one of ordinary skill in the art, and all such analogs are intended to be encompassed by the term as set forth herein.
As used herein, "deuterium" refers to an isotope of hydrogen. Deuterated compounds can be readily prepared using methods known in the art. For example, U.S. patent No. 8,557,400, patent publication No. WO 2006/095951, and U.S. patent application publication No. US 2011/0037057 (which are incorporated herein by reference in their entirety) describe the preparation of deuterium substituted organometallic complexes. With further reference to \37154; (Ming Yan) et al, Tetrahedron (Tetrahedron)2015,71,1425-30 and aztret (Atzrodt) et al, german applied chemistry (angelw. chem. int. ed.) (review) 2007,46,7744-65, which are incorporated by reference in their entirety, describe efficient routes for deuteration of methylene hydrogens in benzyl amines and replacement of aromatic ring hydrogens with deuterium, respectively.
It is understood that when a molecular fragment is described as a substituent or otherwise attached to another moiety, its name can be written as if it were a fragment (e.g., phenyl, phenylene, naphthyl, dibenzofuranyl) or as if it were an entire molecule (e.g., benzene, naphthalene, dibenzofuran). As used herein, these different named substituents or the manner of linking the fragments are considered equivalent.
In some cases, a pair of adjacent substituents may optionally join or be fused to form a ring. Preferred rings are five-, six-or seven-membered carbocyclic or heterocyclic rings, including both cases where a portion of the ring formed by the pair of substituents is saturated and where a portion of the ring formed by the pair of substituents is unsaturated. As used herein, "adjacent" means that the two substituents involved can be on the same ring next to each other, or on two adjacent rings having two nearest available substitutable positions (e.g., the 2, 2' positions in biphenyl or the 1, 8 positions in naphthalene), so long as they can form a stable fused ring system.
B. Compounds of the present disclosure
In one aspect, the present disclosure provides a composition comprising formula I
Figure BDA0003067090940000081
Ligand L ofAThe compound of (1). In the formula I, Z1、Z2、Z3、Z4、Z5And Z6Each is independently C or N;
k is selected from the group consisting of: a direct bond, O and S;
when K is O or S, then Z6Is C;
each of ring a1 and ring a2 is independently a 5-or 6-membered carbocyclic or heterocyclic ring, or a polycyclic fused ring system comprising more than one 5-or 6-membered carbocyclic or heterocyclic ring;
RAand RBEach of which is independently mono-substituted, up to a maximum of allowed substitutions, or no substitution;
ligand LACoordinating to metal M by two indicated dashed lines;
m is selected from the group consisting of: ir, Os, Ru, Rh, Pt, Pd, Cu, Ag, Au, Be, Mg, Al, Ca, Ti, Mn, Co, Zn, Ga, Ge and Zr;
m is coordinated to at least one other ligand;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands;
L1is an organic linking group;
when M is selected from the group consisting of Ru, Os, and Ir, then K is O or S;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is a direct bond, then M forms at least one bond with oxygen or sulfur;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is O or S, then L1Selected from the group consisting of: -CR ═ N-, -CR 'R "-, -NR' BR '-, -CR' R" O-, -CR 'R "S-, -CR' ═ CR" O-, -CR '═ CR "S-, -CR' ═ CR 'NR-, -CR' ═ CR" CR ″2-, -C (═ N-) -, and-C (═ CR-) -, and formula II
Figure BDA0003067090940000091
The structure of (1); ring A3 is a 5-or 6-membered carbocyclic or heterocyclic ring, and contains Z7And Z8Together form a system of 18 pi electrons; z7And Z8Each of which is independently C or N;
each RA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of the general substituents defined herein; and is
Any two adjacent RA、RB、RCR, R' and R "may be joined or fused together to form a ring.
In some embodiments, each R isA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of the preferred general substituents defined herein. In some embodiments, each R isA、RBR, R', R "are independently hydrogen or a substituent selected from the group consisting of the more preferred general substituents defined herein. In some embodiments, each R isA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of the most preferred general substituents defined herein.
In some embodiments, Z3Selected from the group consisting of N and carbene carbon.
In some embodiments, Z6Is C and K is O or S. In some embodiments, Z6Is N and K is a direct bond.
In some embodiments, ring a1 is selected from the group consisting of: imidazoles, benzimidazoles, imidazole-based carbenes, benzimidazole-based carbenes, pyrimidines, pyrazoles, and pyridines.
In some embodiments, ring a2 is selected from the group consisting of: benzene, pyridine, carbazole, benzimidazole, benzothiophene, dibenzothiophene, benzofuran, dibenzofuran, dibenzofluorene, naphthalene, tetrahydronaphthalene, phenoxazine, 9, 10-dihydroacridine, anthracene, and phenanthrene.
In some embodiments, M is selected from the group consisting of Ru, Os, and Ir. In some embodiments, K is O. In some embodiments, K is S.
In some embodiments, M is selected from the group consisting of: pt, Pd, Cu, Ag or Au, and K is a direct bond.
Organic linking group L1Selected from the group consisting of: -X-, -X-X' -, -XL=XL'-and-XL=XL'-X-, wherein X and X' are each independently selected from the group consisting of: BR ', NR ', PR ', O, S, Se, C-O, S-O, SO2CR 'R', SiR 'R' and GeR 'R'; and XLAnd XL'Each independently selected from the group consisting of N and CR'.
In some embodiments, L1is-X-. In some embodiments, L1is-X-X' -. In some embodiments, L1is-XL=XL'-. In some embodiments, L1is-XL=XL'-X-. In some embodiments, the organic linking group L1Having the formula II
Figure BDA0003067090940000101
The structure of (1). In some embodiments, ring a3 is a 6-membered ring. In some embodiments, ring a3 is a 5-membered ring. In some embodiments, formula II is selected from the group consisting of:
Figure BDA0003067090940000102
in some embodiments, RCSelected from R1 to R86 having the structures in table 3 as defined herein.
In some embodiments, at least one of R, R 'or R' and RA、RBOne of, R, R' or R "forms a ring.
In some embodiments, each of R, R' and R "is independently hydrogen or a substituent selected from the group consisting of: alkyl, cycloalkyl, aryl, and combinations thereof.
In some embodiments, M is selected from the group consisting of: pt, Pd, Cu, Ag or Au, and K is S or O. In some such embodiments, L1is-CR ═ N-. In thatIn some such embodiments, L1is-CR 'R' -. In some such embodiments, L1is-NR 'BR' -. In some such embodiments, L1is-CR' R "O-. In some such embodiments, L1is-CR' R "S-. In some such embodiments, at least one of R, R 'or R' and RA、RBOne of, R, R' or R "forms a ring. In some such embodiments, each of R, R' and R "is independently hydrogen or a substituent selected from the group consisting of: alkyl, cycloalkyl, aryl, and combinations thereof.
In some embodiments, ligand LASelected from the group consisting of the structures of table 1 below:
Figure BDA0003067090940000103
Figure BDA0003067090940000111
Figure BDA0003067090940000121
Figure BDA0003067090940000131
Figure BDA0003067090940000141
Figure BDA0003067090940000151
wherein Q may be present or absent, and when present, is a first linking group; and wherein each R isC、R1、R2、R3And R4Independently hydrogen or selected from the group of general substituents defined hereinA substituent of the group.
In some of the above embodiments, the first linking group Q may be selected from the group consisting of: -CR1"R2"-CR3"R4"-、-CR1"R2"-CR3"R4"-CR5"R6"-、-CR1"R2"-NR3"-、-CR1"=CR2"-CR3"R4"-、-O-SiR1"R2"-、-CR1"R2"-S-、-CR1"R2"-O-and-CRr'R2"-SiR3"R4"-; wherein R is1To R6Each of which may be the same or different and is independently selected from the group consisting of: hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof; wherein any adjacent R1To R6May be joined to form a five or six membered ring.
In some of the above embodiments, the first linking group Q may be selected from the group consisting of:
Figure BDA0003067090940000161
Figure BDA0003067090940000171
in some embodiments, ligand LASelected from the group consisting of the following structures, wherein the groups will be collectively referred to as LA,spec:LA1-(Ri)(Rj)(Rk)(Rl)、LA2-(Ri)(Rj)(Rk)(Rl)、LA3-(Ri)(Rj)(Rk)(Rl)、LA4-(Ri)(Rj)(Rk)(Rl)、LA5-(Ri)(Rj)(Rk)(Rl)、LA6-(Ri)(Rj)(Rk)(Rl)、LA7-(Ri)(Rj)、LA8-(Ri)(Rj)、LA9-(Ri)(Rj)、LA10-(Ri)(Rj)、LA11-(Ri)(Rj)、LA12-(Ri)(Rj)、LA13-(Ri)(Rj)、LA14-(Ri)(Rj)、LA15-(Ri)(Rj)、LA16-(Ri)(Rj)、LA17-(Ri)(Rj)、LA18-(Ri)(Rj)、LA19-(Ri)(Rj)、LA20-(Ri)(Rj)、LA21-(Ri)(Rj)、LA22-(Ri)(Rj)、LA23-(Ri)(Rj)、LA24-(Ri)(Rj)、LA25-(Ri)(Rj)、LA26-(Ri)(Rj)、LA27-(Ri)(Rj)、LA28-(Ri)(Rj)、LA29-(Ri)(Rj)、LA30-(Ri)(Rj)、LA31-(Ri)(Rj)、LA32-(Ri)(Rj)、LA33-(Ri)(Rj)、LA34-(Ri)(Rj)、LA35-(Ri)(Rj)、LA36-(Ri)(Rj)、LA37-(Ri)(Rj)、LA38-(Ri)(Rj)、LA39-(Ri)(Rj)、LA40-(Ri)(Rj)、LA41-(Ri)(Rj)(Rk)、LA42-(Ri)(Rj)(Rk)、LA43-(Ri)(Rj)、LA44-(Ri)(Rj)、LA45-(Ri)(Rj)、LA46-(Ri)(Rj)、LA47-(Ri)(Rj)、LA48-(Ri)(Rj)、LA49-(Ri)(Rj)、LA50-(Ri)(Rj)、LA51-(Ri)(Rj)(Rk)、LA52-(Ri)(Rj)(Rk)、LA53-(Ri)(Rj)(Rk)、LA54-(Ri)(Rj)(Rk)、LA55-(Ri)(Rj)(Rk)、LA56-(Ri)(Rj)(Rk)、LA57-(Ri)(Rj)(Rk)、LA58-(Ri)(Rj)(Rk)、LA59-(Ri)(Rj)(Rk)、LA60-(Ri)(Rj)(Rk)、LA61-(Ri)(Rj)(Rk)、LA62-(Ri)(Rj)(Rk)、LA63-(Ri)(Rj)(Rk)、LA64-(Ri)(Rj)(Rk)、LA65-(Ri)、LA66-(Ri)、LA67-(Ri)、LA68-(Ri)、LA69-(Ri)、LA70-(Ri)、LA71-(Ri)、LAa1-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa2-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa3-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa4-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa5-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa6-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)、LAa7-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)、LAa8-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa9-X(j)(k)(l)(m)(n)(o)(p)(q)、LAa10-X(j)(k)(l)(m)(n)(o)(p)(q)、LAa11-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa12-X(i)(j)(k)(l)(m)(n)(o)(p)、LAa13-X(j)(k)(l)(m)(n)(o)(p)、LAa14-X(j)(k)(l)(m)(n)(o)(p)、LAa15-X(i)(j)(k)(l)(m)(n)(o)(p)、LAa16-X(i)(j)(k)(l)(m)(n)(o)(p)、LAa17-X(j)(k)(l)(m)(n)(o)(p)、LAa18-X(j)(k)(l)(m)(n)(o)(p)、LAa19-X(i)(j)(k)(l)(m)(n)(o)(p)、LAa20-X(i)(j)(k)(l)(m)(n)(o)、LAa21-X(j)(k)(l)(m)(n)(o)、LAa22-X(j)(k)(l)(m)(n)(o)、LAa23-X(i)(j)(k)(l)(m)(n)(o)、LAa24-X(j)(k)(l)(m)(n)(o)(p)、LAa25-X(i)(j)(k)(l)(m)(n)(o)(p)、LAa26-X(j)(k)(l)(m)(n)(o)(p)、LAa27-X(i)(j)(k)(l)(m)(n)(o)(p)、LAa28-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa29-X(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa30-X(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa31-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa32-X(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa33-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa34-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)、LAa35-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)、LAa36-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa37-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa38-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa39-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa40-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa41-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa42-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa43-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa44-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)(t)、LAa45-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)(t)、LAa46-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)(s)(t)、LAa47-X(i)(j)(k)(l)(m)(n)(o)(p)(q)(r)、LAa48-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa49-X(i)(j)(k)(l)(n)(o)(p)(q)、LAa50-X(i)(j)(k)(l)(m)(n)(o)(p)(q)、LAa51-X(i)(j)(k)(l)(n)(o)(p)(q)、LAa52-X(i)(j)(k)(l)(m)(n)(q)(u)(v)(w)(x)、LAa53-X(i)(j)(k)(l)(m)(p)(u)(v)(w)(x)、LAa54-X(j)(k)(l)(m)(p)(u)(v)(w)(x)、LAa55-X(j)(k)(l)(m)(p)(u)(v)(w)(x)、LAa56-X(i)(j)(k)(l)(m)(p)(u)(v)(w)(x)、LAa57-X(j)(k)(l)(m)(p)(u)(v)(w)(x)、LAa58-X(i)(j)(k)(l)(m)(n)(o)(r)(u)(v)(w)(x)、LAa59-X (i), (j) (k) (L) (m) (n) (o) (u) (v) (w) (x), wherein each of i, j, k, L, m, n, o, p, q, r, s, t, u, v, w and x is independently an integer from 1 to 86, and wherein the group LA,specEach ligand L in (1)AIs defined by the following table 2:
Figure BDA0003067090940000191
Figure BDA0003067090940000201
Figure BDA0003067090940000211
Figure BDA0003067090940000221
Figure BDA0003067090940000231
Figure BDA0003067090940000241
Figure BDA0003067090940000251
Figure BDA0003067090940000261
Figure BDA0003067090940000271
Figure BDA0003067090940000281
Figure BDA0003067090940000291
Figure BDA0003067090940000301
Figure BDA0003067090940000311
Figure BDA0003067090940000321
Figure BDA0003067090940000331
Figure BDA0003067090940000341
Figure BDA0003067090940000351
Figure BDA0003067090940000361
Figure BDA0003067090940000371
Figure BDA0003067090940000381
Figure BDA0003067090940000391
Figure BDA0003067090940000401
Figure BDA0003067090940000411
wherein Ph represents a phenyl group; and is
Wherein the structures of R1 through R86 are defined in the following table 3:
Figure BDA0003067090940000421
Figure BDA0003067090940000431
in some embodiments, ligand LASelected from the group consisting of: l isA1-(R33)(R2)(R1)(R1)、LA2-(R33)(R2)(R1)(R1)、LA1-(R33)(R6)(R1)(R1)、LA2-(R33)(R6)(R1)(R1)、LA3-(R33)(R2)(R1)(R1)、LA4-(R33)(R2)(R1)(R1)、LA1-(R49)(R2)(R1)(R1)、LA2-(R49)(R2)(R1)(R1)、LA1-(R30)(R2)(R1)(R1)、LA2-(R30)(R2)(R1)(R1)、LA1-(R30)(R6)(R1)(R1)、LA2-(R30)(R6)(R1)(R1)、LA1-(R30)(R28)(R1)(R1)、LA2-(R30)(R28)(R1)(R1)、LA1-(R33)(R28)(R1)(R1)、LA2-(R33)(R28)(R1)(R1)、LA45-(R33)(R2)、LA46-(R33)(R2)、LA9-(R33)(R1)、LA10-(R33)(R1)、LA11-(R33)(R1)、LA12-(R33)(R1)、LA13-(R33)(R1)、LA14-(R33)(R1)、LA21-(R33)(R1)、LA22-(R33)(R1)、LA33-(R33)(R1)、LA34-(R33)(R1)、LA41-(R48)(R1)(R1)、LA65-(R2)、LA66-(R2)、LA67-(R2)、LA68-(R2)、LA69-(R3)、LA70-(R3)、LA61-(R2)(R1)(R1)、LA62-(R2)(R1)(R1)、LA59-(R2)(R1)(R1)、LA59-(R3)(R1)(R1)、LA60-(R2)(R1)(R1)、LA60-(R3)(R1)(R1)、LA4-(R33)(R2)(R1)(R1)、LA43- (R33) (R2) and LA44-(R33)(R2)。
In some embodiments, the compound has formula M (L)A)p(LB)q(LC)rWherein L isBAnd LCEach is a bidentate ligand; and wherein p is 1,2 or 3; q is 0, 1 or 2; r is 0, 1 or 2; and p + q + r is the oxidation state of the metal M.
In some embodiments, the compound has a formula selected from the group consisting of: ir (L)A)3、Ir(LA)(LB)2、Ir(LA)2(LB)、Ir(LA)2(LC) And Ir (L)A)(LB)(LC) (ii) a And wherein LA、LBAnd LCAre different from each other. In some embodiments, M is Ir, LBIs a substituted or unsubstituted phenylpyridine, and LCIs a substituted or unsubstituted acetylacetonate.
In some embodiments, the compound has the formula Pt (L)A)(LB) (ii) a And wherein LAAnd LBMay be the same or different. In some such embodiments, LAAnd LBLinked to form a tetradentate ligand.
In some embodiments, LBAnd LCEach independently selected from the group consisting of the structures of table 4 below:
Figure BDA0003067090940000441
Figure BDA0003067090940000451
Figure BDA0003067090940000461
wherein:
t is selected from the group consisting of: B. al, Ga and In;
Y1to Y13Each of which is independently selected from the group consisting of carbon and nitrogen;
y' is selected from the group consisting of: BR (BR)e、NRe、PRe、O、S、Se、C=O、S=O、SO2、CReRf、SiReRfAnd GeReRf
ReAnd RfMay be fused or joined to form a ring;
each Ra、Rb、RcAnd RdIndependently represent zero substitution, mono substitution, or up to the maximum allowed number of substitutions for its associated ring;
Ra1、Rb1、Rc1、Rd1、Ra、Rb、Rc、Rd、Reand RfEach of which is independently hydrogen or a substituent selected from the group consisting of the general substituents defined herein; and is
Any two adjacent Ra、Rb、Rc、Rd、ReAnd RfMay be fused or joined to form a ring or to form a multidentate ligand.
In some embodiments, LBAnd LCEach independently selected from the group consisting of the structures of table 5 below:
Figure BDA0003067090940000471
Figure BDA0003067090940000481
Figure BDA0003067090940000491
Figure BDA0003067090940000501
wherein: ra'、Rb'、Rc'、Rd'、Re'、Rf'、Rg' and Rn' each independently represents zero, mono, or up to the maximum permissible substitution of its associated ring; ra1、Rb1、Rc1、Ra、Rb、Rc、Ra'、Rb'、Rc'、Rd'、Re'、Rf'、Rg' and RnEach of' is independently hydrogen or a substituent selected from the group consisting of the preferred general substituents defined herein; and two adjacent Ra'、Rb'、Rc'、Rd'、Re'、Rf'、Rg' and Rn' may be fused or joined to form a ring or to form a multidentate ligand.
In some embodiments, when the compound has the formula Ir (L)A)3When L isAIs selected from the group consisting of LA,specAnd a compound selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))3To Ir (L)A71-(R86))3A group of combinations thereof. Using group LA,specEach ligand L in (1)ANomenclature of (1), from Ir (L)A1-(R1)(R1)(R1)(R1))3To Ir (L)A71-(R86))3The group of compounds of which is also written Ir (L)A1-(R1)(R1)(R1)(R1))3To Ir (L)A1-(R86)(R86)(R86)(R86))3、Ir(LA2-(R1)(R1)(R1)(R1))3To Ir (L)A2-(R86)(R86)(R86)(R86))3、Ir(LA3-(R1)(R1)(R1)(R1))3To Ir (L)A3-(R86)(R86)(R86)(R86))3、Ir(LA4-(R1)(R1)(R1)(R1))3To Ir (L)A4-(R86)(R86)(R86)(R86))3、Ir(LA5-(R1)(R1)(R1)(R1))3To Ir (L)A5-(R86)(R86)(R86)(R86))3、Ir(LA6-(R1)(R1)(R1)(R1))3To Ir (L)A6-(R86)(R86)(R86)(R86))3、Ir(LA7-(R1)(R1))3To Ir (L)A7-(R86)(R86))3、Ir(LA8-(R1)(R1))3To Ir (L)A8-(R86)(R86))3、Ir(LA9-(R1)(R1))3To Ir (L)A9-(R86)(R86))3、Ir(LA10-(R1)(R1))3To Ir (L)A10-(R86)(R86))3、Ir(LA11-(R1)(R1))3To Ir (L)A11-(R86)(R86))3、Ir(LA12-(R1)(R1))3To Ir (L)A12-(R86)(R86))3、Ir(LA13-(R1)(R1))3To Ir (L)A13-(R86)(R86))3、Ir(LA14-(R1)(R1))3To Ir (L)A14-(R86)(R86))3、Ir(LA15-(R1)(R1))3To Ir (L)A15-(R86)(R86))3、Ir(LA16-(R1)(R1))3To Ir (L)A16-(R86)(R86))3、Ir(LA17-(R1)(R1))3To Ir (L)A17-(R86)(R86))3、Ir(LA18-(R1)(R1))3To Ir (L)A18-(R86)(R86))3、Ir(LA19-(R1)(R1))3To Ir (L)A19-(R86)(R86))3、Ir(LA20-(R1)(R1))3To Ir (L)A20-(R86)(R86))3、Ir(LA21-(R1)(R1))3To Ir (L)A21-(R86)(R86))3、Ir(LA22-(R1)(R1))3To Ir (L)A22-(R86)(R86))3、Ir(LA23-(R1)(R1))3To Ir (L)A23-(R86)(R86))3、Ir(LA24-(R1)(R1))3To Ir (L)A24-(R86)(R86))3、Ir(LA25-(R1)(R1)3To Ir (L)A25-(R86)(R86)3、Ir(LA26-(R1)(R1))3To Ir (L)A26-(R86)(R86))3、Ir(LA27-(R1)(R1))3To Ir (L)A27-(R86)(R86))3、Ir(LA28-(R1)(R1))3To Ir (L)A28-(R86)(R86))3、Ir(LA29-(R1)(R1))3To Ir (L)A29-(R86)(R86))3、Ir(LA30-(R1)(R1))3To Ir (L)A30-(R86)(R86))3、Ir(LA31-(R1)(R1))3To Ir (L)A31-(R86)(R86))3、Ir(LA32-(R1)(R1))3To Ir (L)A32-(R86)(R86))3、Ir(LA33-(R1)(R1))3To Ir (L)A33-(R86)(R86))3、Ir(LA34-(R1)(R1))3To Ir (L)A34-(R86)(R86))3、Ir(LA35-(R1)(R1))3To Ir (L)A35-(R86)(R86))3、Ir(LA36-(R1)(R1))3To Ir (L)A36-(R86)(R86))3、Ir(LA37-(R1)(R1))3To Ir (L)A37-(R86)(R86))3、Ir(LA38-(R1)(R1))3To Ir (L)A38-(R86)(R86))3、Ir(LA39-(R1)(R1))3To Ir (L)A39-(R86)(R86))3、Ir(LA40-(R1)(R1))3To Ir (L)A40-(R86)(R86))3、Ir(LA41-(R1)(R1)(R1))3To Ir (L)A41-(R86)(R86)(R86))3、Ir(LA42-(R1)(R1)(R1))3To Ir (L)A42-(R86)(R86)(R86))3、Ir(LA43-(R1)(R1))3To Ir (L)A43-(R86)(R86))3、Ir(LA44-(R1)(R1))3To Ir (L)A44-(R86)(R86))3、Ir(LA45-(R1)(R1))3To Ir (L)A45-(R86)(R86))3、Ir(LA46-(R1)(R1))3To Ir(LA46-(R86)(R86))3、Ir(LA47-(R1)(R1))3To Ir (L)A47-(R86)(R86))3、Ir(LA48-(R1)(R1))3To Ir (L)A48-(R86)(R86))3、Ir(LA49-(R1)(R1))3To Ir (L)A49-(R86)(R86))3、Ir(LA50-(R1)(R1))3To Ir (L)A50-(R86)(R86))3、Ir(LA51-(R1)(R1)(R1))3To Ir (L)A51-(R86)(R86)(R86))3、Ir(LA52-(R1)(R1)(R1))3To Ir (L)A52-(R86)(R86)(R86))3、Ir(LA53-(R1)(R1)(R1))3To Ir (L)A53-(R86)(R86)(R86))3、Ir(LA54-(R1)(R1)(R1))3To Ir (L)A54-(R86)(R86)(R86))3、Ir(LA55-(R1)(R1)(R1))3To Ir (L)A55-(R86)(R86)(R86))3、Ir(LA56-(R1)(R1)(R1))3To Ir (L)A56-(R86)(R86)(R86))3、Ir(LA57-(R1)(R1)(R1))3To Ir (L)A57-(R86)(R86)(R86))3、Ir(LA58-(R1)(R1)(R1))3To Ir (L)A58-(R86)(R86)(R86))3、Ir(LA59-(R1)(R1)(R1))3To Ir (L)A59-(R86)(R86)(R86))3、Ir(LA60-(R1)(R1)(R1))3To Ir (L)A60-(R86)(R86)(R86))3、Ir(LA61-(R1)(R1)(R1))3To Ir (L)A61-(R86)(R86)(R86))3、Ir(LA62-(R1)(R1)(R1))3To Ir (L)A62-(R86)(R86)(R86))3、Ir(LA63-(R1)(R1)(R1))3To Ir (L)A63-(R86)(R86)(R86))3、Ir(LA64-(R1)(R1)(R1))3To Ir (L)A64-(R86)(R86)(R86))3、Ir(LA65-(R1))3To Ir (L)A65-(R86))3、Ir(LA66-(R1))3To Ir (L)A66-(R86))3、Ir(LA67-(R1))3To Ir (L)A67-(R86))3、Ir(LA68-(R1))3To Ir (L)A68-(R86))3、Ir(LA69-(R1))3To Ir (L)A69-(R86))3、Ir(LA70-(R1))3To Ir (L)A70-(R86))3And Ir (L)A71-(R1))3To Ir (L)A71-(R86))3
In some embodiments, when the compound has the formula Ir (L)A)(LBk)2When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); wherein k is an integer from 1 to 540; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))(LB1)2To Ir (L)A71-(R86))(LB540)2Group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))(LB1)2To Ir (LA71- (R86)) (L)B540)2Each compound of the group may use group LA,specEach ligand L in (1)AFor the formula Ir (L)A)3The compounds are written in a similar manner as indicated above.
In some embodiments, when the compound has the formula Ir (L)A)2(LBk) When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); wherein k is an integer from 1 to 540; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LB1) To Ir (L)A71-(R86))2(LB540) Group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LB1) to Ir (L)A71-(R86))2(LB540) Each compound of the group may use group LA,specEach ligand L in (1)AFor the formula Ir (L)A)3The compounds are written in a similar manner as indicated above.
In some embodiments, when the compound has the formula Ir (L)A)2(LCj-I) When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); wherein j is an integer from 1 to 1416; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LC1-I) To Ir (L)A71-(R86))(LC1416-I) Group ofGroup, wherein is composed of Ir (L)A1-(R1)(R1)(R1)(R1))2(LC1-I) To Ir (L)A71-(R86))(LC1416-I) Each compound of the group may use group LA,specEach ligand L in (1)AFor the formula Ir (L)A)3The compounds are written in a similar manner as indicated above.
In some embodiments, when the compound has the formula Ir (L)A)2(LCj-II) When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); wherein j is an integer from 1 to 1416; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LC1-II) To Ir (L)A71-(R86))(LC1416-II) Group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LC1-II) To Ir (L)A71-(R86))(LC1416-II) Each compound of the group may use group LA,specEach ligand L in (1)AFor the formula Ir (L)A)3The compounds are written in a similar manner as indicated above.
In each of the embodiments of the compounds disclosed herein, wherein the compound comprises one or more ligands LBkWherein k is an integer from 1 to 540, each LBkHaving the structure defined in the following table 6:
Figure BDA0003067090940000531
Figure BDA0003067090940000541
Figure BDA0003067090940000551
Figure BDA0003067090940000561
Figure BDA0003067090940000571
Figure BDA0003067090940000581
Figure BDA0003067090940000591
Figure BDA0003067090940000601
Figure BDA0003067090940000611
Figure BDA0003067090940000621
Figure BDA0003067090940000631
Figure BDA0003067090940000641
Figure BDA0003067090940000651
Figure BDA0003067090940000661
Figure BDA0003067090940000671
Figure BDA0003067090940000681
Figure BDA0003067090940000691
Figure BDA0003067090940000701
Figure BDA0003067090940000711
Figure BDA0003067090940000721
Figure BDA0003067090940000731
Figure BDA0003067090940000741
Figure BDA0003067090940000751
Figure BDA0003067090940000761
in each of the embodiments of the compounds disclosed herein, wherein the compound comprises one or more ligands LCj-IAnd/or LCj-IIWherein j is an integer from 1 to 1416, each LCj-IHas a formula based on
Figure BDA0003067090940000762
The structure of (1); and is
Each LCj-IIHas a formula based on
Figure BDA0003067090940000763
In respect of L, whereinCj-IAnd LCj-IIEach L inCj,R201And R202Each independently defined in the following table 7:
Figure BDA0003067090940000771
Figure BDA0003067090940000781
Figure BDA0003067090940000791
Figure BDA0003067090940000801
Figure BDA0003067090940000811
Figure BDA0003067090940000821
Figure BDA0003067090940000831
Figure BDA0003067090940000841
Figure BDA0003067090940000851
Figure BDA0003067090940000861
Figure BDA0003067090940000871
Figure BDA0003067090940000881
Figure BDA0003067090940000891
wherein R isD1To RD246Having the structure in table 8 below:
Figure BDA0003067090940000892
Figure BDA0003067090940000901
Figure BDA0003067090940000911
Figure BDA0003067090940000921
Figure BDA0003067090940000931
in some embodiments, the compound has the formula Ir (L)A)(LBk)2Or Ir (L)A)2(LBk) Wherein the compound is selected from the group consisting ofBkA ligand of one of the following structures: l isB1、LB2、LB18、LB28、LB38、LB108、LB118、LB122、LB124、LB126、LB128、LB130、LB32、LB134、LB136、LB138、LB140、LB142、LB144、LB156、LB58、LB160、LB162、LB164、LB168、LB172、LB175、LB204、LB206、LB214、LB216、LB218、LB220、LB222、LB231、LB233、LB235、LB237、LB240、LB242、LB244、LB246、LB248、LB250、LB252、LB254、LB256、LB258、LB260、LB262、LB263、LB264、LB265、LB266、LB267、LB268、LB269And LB270
In some embodiments, the compound has the formula Ir (L)A)(LBk)2Or Ir (L)A)2(LBk) Wherein the compound is selected from the group consisting ofBkA ligand of one of the following structures: l isB1、LB2、LB18、LB28、LB38、LB108、LB118、LB122、LB124、LB126、LB128、LB132、LB136、LB138、LB142、LB156、LB162、LB204、LB206、LB214、LB216、LB218、LB220、LB231、LB233、LB237、LB265、LB266、LB267、LB268、LB269And LB270
In some embodiments, LCj-IAnd LCj-IIEach independently selected from only the corresponding R in its corresponding group201And R202Those structures that are one of the following structures: rD1、RD3、RD4、RD5、RD9、RD10、RD17、RD18、RD20、RD22、RD37、RD40、RD41、RD42、RD43、RD48、RD49、RD50、RD54、RD55、RD58、RD59、RD78、RD79、RD81、RD87、RD88、RD89、RD93、RD116、RD117、RD118、RD119、RD120、RD133、RD134、RD135、RD136、RD143、RD144、RD145、RD146、RD147、RD149、RD151、RD154、RD155、RD161、RD175、RD190、RD193、RD200、RD201、RD206、RD210、RD214、RD215、RD216、RD218、RD219、RD220、RD227、RD237、RD241、RD242、RD245And RD246
In some embodiments, LCj-IAnd LCj-IIEach independently selected from only the corresponding R in its corresponding group201And R202Those structures selected from one of the following structures: rD1、RD3、RD4、RD5、RD9、RD10、RD17、RD22、RD43、RD50、RD78、RD116、RD118、RD133、RD134、RD135、RD136、RD143、RD144、RD145、RD146、RD149、RD151、RD154、RD155、RD190、RD193、RD200、RD201、RD206、RD210、RD214、RD215、RD216、RD218、RD219、RD220、RD227、RD237、RD241、RD242、RD245And RD246
In some embodiments, the compound has the formula Ir (L)A)2(LCj-I) And the compound is selected from the group consisting of compounds having L onlyCj-IA ligand of the group consisting of those compounds of one of the structures of table 9 below:
Figure BDA0003067090940000941
Figure BDA0003067090940000951
in some embodiments, the compound is selected from the group consisting of the structures of table 10 below:
Figure BDA0003067090940000952
Figure BDA0003067090940000961
Figure BDA0003067090940000971
Figure BDA0003067090940000981
Figure BDA0003067090940000991
Figure BDA0003067090940001001
Figure BDA0003067090940001011
in some embodiments, the compound has the structure of formula II,
Figure BDA0003067090940001021
in the structure of formula II:
M1is Pd or Pt;
rings E and F are each independently a 5-or 6-membered carbocyclic or heterocyclic ring;
z and Z' are each independently C or N;
K1and K2Each independently selected from the group consisting of: a direct bond, O and S, wherein K1And K2At least one of which is a direct bond;
L1is an organic linking group;
L2、L3and L4Each independently selected from the group consisting of: single bond, absent bond, O, S, CR 'R', SiR 'R', BR 'and NR', where L2、L3And L4Is present;
X3and X4Each independently is C or N;
REand RFEach independently represents zero substitution, mono substitution, or up to the maximum permissible substitution for its associated ring;
R'、R"、REand RFEach of which is independently hydrogen or a substituent selected from the group consisting of the preferred general substituents defined herein;
any two adjacent RA、RB、R、R'、R”、REAnd RFMay be joined or fused together to form a ring.
In some embodiments of formula II, ring E and ring F are both 6-membered aromatic rings.
In some embodiments of formula II, ring F is a 5-or 6-membered heteroaryl ring.
In some embodiments of formula II, L1Is O or CR' R ".
In some embodiments of formula II, Z' is N and Z is C. In some embodiments of formula II, Z' is C and Z is N.
In some embodiments of formula II, L2Is a direct bond. In some embodiments of formula II, L2Is NR'.
In some embodiments of formula II, K1And K2Are all direct bonds.
In some embodiments of formula II, X3And X4Are all C.
In some embodiments, the compound is selected from the group consisting of the structures in table 11 below:
Figure BDA0003067090940001031
Figure BDA0003067090940001041
Figure BDA0003067090940001051
wherein: l is1aSelected from the group of: -CR ═ N-, -CR 'R "-, -NR' BR-, -CR 'R" O-, -CR' R "S-, -CR '═ CR" O-, -CR' ═ CR "S-, -CR '═ CR" NR-, -CR' ═ CR "CR ″2-, -C (═ CR-) -, and-C (═ N-) -;
L1bselected from the group of: -CR ═ N-, -CR2-、-CR=CR'-、-CR'R"CR'R"-、-NR'BR'-、-CR'R"O-、-CR'R"S-、-CR'=CR"O-、-CR'=CR"S-、-CR'=CR"NR-、-CR'=CR"CR2-, -C (-CR-) -, -C (-N-) -, and formula II
Figure BDA0003067090940001052
The structure of (1);
RYeach selected from the group consisting of: alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl, and combinations thereof;
each RGIndependently hydrogen or a substituent selected from the group consisting of the preferred general substituents defined herein; and is
Any two RA、RB、RC、RE、RF、RG、RYR, R' and R "may be joined together to form a ring.
In some embodiments, the compound is selected from the group consisting of the structures in table 12 below:
Figure BDA0003067090940001053
Figure BDA0003067090940001061
Figure BDA0003067090940001071
Figure BDA0003067090940001081
Figure BDA0003067090940001091
Figure BDA0003067090940001101
Figure BDA0003067090940001111
Figure BDA0003067090940001121
C. OLEDs and devices of the present disclosure
In another aspect, the present disclosure also provides an OLED device comprising a first organic layer comprising a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the OLED comprises an anode, a cathode, and a first organic layer disposed between the anode and the cathode. The first organic layer can contain a ligand L comprising formula I described hereinAThe compound of (1).
In some embodiments, the organic layer may be an emissive layer and the compound as described herein may be an emissive dopant or a non-emissive dopant.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a triphenylene comprising a benzo-fused thiophene or a benzo-fused furan, wherein any substituent in the host is a non-fused substituent independently selected from the group consisting of: cnH2n+1、OCnH2n+1、OAr1、N(CnH2n+1)2、N(Ar1)(Ar2)、CH=CH-CnH2n+1、C≡CCnH2n+1、Ar1、Ar1-Ar2、CnH2n-Ar1Or no substituent, wherein n is 1 to 10; and wherein Ar1And Ar2Independently selected from the group consisting of: benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises at least one chemical group selected from the group consisting of: triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5, 9-dioxa-13 b-boranaphtho [3,2,1-de ] anthracene, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, and aza- (5, 9-dioxa-13 b-boranaphtho [3,2,1-de ] anthracene).
In some embodiments, the subject may be selected from the group of subjects consisting of:
Figure BDA0003067090940001131
Figure BDA0003067090940001141
Figure BDA0003067090940001151
Figure BDA0003067090940001152
and combinations thereof.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a metal complex.
In some embodiments, a compound as described herein may be a sensitizer; wherein the device may further comprise a receptor; and wherein the receptor may be selected from the group consisting of: fluorescent emitters, delayed fluorescent emitters, and combinations thereof.
In yet another aspect, the OLEDs of the present disclosure can further comprise an emissive region comprising a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the emissive region can contain a ligand L comprising formula I described hereinAThe compound of (1).
In some embodiments, at least one of the anode, cathode, or new layer disposed over the organic emissive layer serves as an enhancement layer. The enhancement layer includes a plasmonic material exhibiting surface plasmon resonance that couples non-radiatively to the emitter material and transfers excited state energy from the emitter material to a non-radiative mode of surface plasmon polaritons. The enhancement layer is disposed at a distance from the organic emissive layer that does not exceed a threshold distance, wherein the emitter material has an overall non-radiative decay rate constant and an overall radiative decay rate constant due to the presence of the enhancement layer, and the threshold distance is where the overall non-radiative decay rate constant equals the overall radiative decay rate constant. In some embodiments, the OLED further comprises an outcoupling layer. In some embodiments, the outcoupling layer is disposed on the enhancement layer on the opposite side of the organic emission layer. In some embodiments, the outcoupling layer is disposed on the opposite side of the emission layer from the enhancement layer, but is still capable of outcoupling energy from surface plasmon modes of the enhancement layer. The outcoupling layer scatters energy from surface plasmon polaritons. In some embodiments, this energy is scattered into free space as photons. In other embodiments, energy is scattered from a surface plasmon mode of the device into other modes, such as, but not limited to, an organic waveguide mode, a substrate mode, or another waveguide mode. If the energy is scattered into a non-free space mode of the OLED, other outcoupling schemes can be incorporated to extract the energy into free space. In some embodiments, one or more intervening layers may be disposed between the enhancement layer and the outcoupling layer. Examples of intervening layers may be dielectric materials, including organic, inorganic, perovskite, oxides, and may include stacks and/or mixtures of these materials.
The enhancement layer changes the effective characteristics of the medium in which the emitter material resides, thereby causing any or all of the following: reduced emissivity, linear change in emission, angular change in emission intensity, change in emitter material stability, change in OLED efficiency, and reduced roll-off efficiency of the OLED device. Placing the enhancement layer on the cathode side, the anode side, or both sides results in an OLED device that takes advantage of any of the effects described above. In addition to the specific functional layers mentioned herein and illustrated in the various OLED examples shown in the figures, OLEDs according to the present disclosure may also include any other functional layers that are common in OLEDs.
The enhancement layer may comprise a plasmonic material, an optically active metamaterial or a hyperbolic metamaterial. As used herein, a plasmonic material is a material in which the real part of the dielectric constant crosses zero in the visible or ultraviolet region of the electromagnetic spectrum. In some embodiments, the plasmonic material comprises at least one metal. In such embodiments, the metal may include at least one of: ag. Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, Ca, alloys or mixtures of these materials, and stacks of these materials. In general, a metamaterial is a medium composed of different materials, wherein the medium as a whole acts differently than the sum of its material parts. Specifically, we define an optically active metamaterial as a material having both negative permittivity and negative permeability. On the other hand, hyperbolic metamaterials are anisotropic media in which the permittivity or permeability has different signs for different spatial directions. Optically active metamaterials and hyperbolic metamaterials are strictly distinguished from many other photonic structures, such as Distributed Bragg reflectors ("DBRs"), because the medium should appear uniform in the propagation direction on the length scale of the optical wavelength. Using terminology understood by those skilled in the art: the dielectric constant of the metamaterial in the propagation direction can be described by an effective medium approximation. Plasmonic and metamaterial materials provide a means for controlling light propagation that can enhance OLED performance in a variety of ways.
In some embodiments, the reinforcement layer is provided as a planar layer. In other embodiments, the enhancement layer has features of wavelength size arranged periodically, quasi-periodically, or randomly, or features of sub-wavelength size arranged periodically, quasi-periodically, or randomly. In some embodiments, the wavelength-sized features and the sub-wavelength-sized features have sharp edges.
In some embodiments, the outcoupling layer has features of wavelength size that are arranged periodically, quasi-periodically, or randomly, or features of sub-wavelength size that are arranged periodically, quasi-periodically, or randomly. In some embodiments, the outcoupling layer may be composed of a plurality of nanoparticles, and in other embodiments, the outcoupling layer is composed of a plurality of nanoparticles disposed over the material. In these embodiments, the out-coupling may be adjusted by at least one of the following: varying a size of the plurality of nanoparticles, varying a shape of the plurality of nanoparticles, varying a material of the plurality of nanoparticles, adjusting a thickness of the material, varying a refractive index of the material or an additional layer disposed on the plurality of nanoparticles, varying a thickness of the enhancement layer, and/or varying a material of the enhancement layer. The plurality of nanoparticles of the device may be formed from at least one of: a metal, a dielectric material, a semiconductor material, a metal alloy, a mixture of dielectric materials, a stack or a laminate of one or more materials, and/or a core of one type of material and coated with a shell of another type of material. In some embodiments, the outcoupling layer is composed of at least metal nanoparticles, wherein the metal is selected from the group consisting of: ag. Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, Ca, alloys or mixtures of these materials, and stacks of these materials. The plurality of nanoparticles may have an additional layer disposed thereon. In some embodiments, an outcoupling layer may be used to adjust the polarization of the emission. Varying the size and periodicity of the outcoupling layer can select the type of polarization that is preferentially outcoupled to air. In some embodiments, the outcoupling layer also serves as an electrode of the device.
In yet another aspect, the present disclosure also provides a consumer product comprising an Organic Light Emitting Device (OLED) having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer can comprise a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the consumer product comprises an OLED having an anode; a cathode; and is arranged on the male partAn organic layer between the electrode and the cathode, wherein the organic layer may contain a ligand L comprising formula I described hereinAThe compound of (1).
In some embodiments, the consumer product may be one of the following: a flat panel display, a computer monitor, a medical monitor, a television, a billboard, a light for interior or exterior lighting and/or signaling, a heads-up display, a fully or partially transparent display, a flexible display, a laser printer, a telephone, a cellular telephone, a tablet, a phablet, a Personal Digital Assistant (PDA), a wearable device, a laptop computer, a digital camera, a video camera, a viewfinder, a microdisplay at a diagonal of less than 2 inches, a 3-D display, a virtual reality or augmented reality display, a vehicle, a video wall containing multiple displays tiled together, a theater or stadium screen, a phototherapy device, and a sign.
Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When current is applied, the anode injects holes and the cathode injects electrons into the organic layer. The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and a hole are located on the same molecule, an "exciton," which is a localized electron-hole pair with an excited energy state, is formed. When the exciton relaxes by a light emission mechanism, light is emitted. In some cases, the exciton may be localized on an excimer (eximer) or an exciplex. Non-radiative mechanisms (such as thermal relaxation) may also occur, but are generally considered undesirable.
Several OLED materials and configurations are described in U.S. patent nos. 5,844,363, 6,303,238, and 5,707,745, which are incorporated herein by reference in their entirety.
The initial OLEDs used emissive molecules that emit light from a singlet state ("fluorescence"), as disclosed, for example, in U.S. patent No. 4,769,292, which is incorporated by reference in its entirety. Fluorescence emission typically occurs in a time frame of less than 10 nanoseconds.
More recently, OLEDs having emissive materials that emit light from the triplet state ("phosphorescence") have been demonstrated. Baldo et al, "high efficiency Phosphorescent Emission from Organic Electroluminescent Devices" (Nature), 395, 151-154,1998 ("Baldo-I"); and baldo et al, "Very high-efficiency green organic light-emitting devices based on electrophosphorescence (Very high-efficiency green organic light-emitting devices-based on electrophosphorescence)", applied physical promo (appl. phys. lett.), volume 75, stages 3,4-6 (1999) ("baldo-II"), which are incorporated by reference in their entirety. Phosphorescence is described in more detail in U.S. Pat. No. 7,279,704, columns 5-6, which is incorporated by reference.
Fig. 1 shows an organic light emitting device 100. The figures are not necessarily to scale. Device 100 can include substrate 110, anode 115, hole injection layer 120, hole transport layer 125, electron blocking layer 130, emissive layer 135, hole blocking layer 140, electron transport layer 145, electron injection layer 150, protective layer 155, cathode 160, and blocking layer 170. Cathode 160 is a composite cathode having a first conductive layer 162 and a second conductive layer 164. The device 100 may be fabricated by depositing the layers in sequence. The nature and function of these various layers and example materials are described in more detail in U.S. Pat. No. 7,279,704, columns 6-10, which is incorporated by reference.
More instances of each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is doped with F at a molar ratio of 50:14TCNQ m-MTDATA as disclosed in U.S. patent application publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of luminescent and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al, which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. patent application publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. patent incorporated by reference in its entiretyExamples of cathodes including composite cathodes having a thin layer of metal (e.g., Mg: Ag) with an overlying transparent, conductive, sputter-deposited ITO layer are disclosed in U.S. Pat. nos. 5,703,436 and 5,707,745. The theory and use of barrier layers is described in more detail in U.S. patent No. 6,097,147 and U.S. patent application publication No. 2003/0230980, which are incorporated by reference in their entirety. Examples of injection layers are provided in U.S. patent application publication No. 2004/0174116, which is incorporated by reference in its entirety. A description of the protective layer may be found in U.S. patent application publication No. 2004/0174116, which is incorporated by reference in its entirety.
Fig. 2 shows an inverted OLED 200. The device includes a substrate 210, a cathode 215, an emissive layer 220, a hole transport layer 225, and an anode 230. The device 200 may be fabricated by depositing the layers in sequence. Because the most common OLED configuration has a cathode disposed above an anode, and device 200 has a cathode 215 disposed below an anode 230, device 200 may be referred to as an "inverted" OLED. Materials similar to those described with respect to device 100 may be used in corresponding layers of device 200. Fig. 2 provides one example of how some layers may be omitted from the structure of device 100.
The simple layered structure illustrated in fig. 1 and 2 is provided by way of non-limiting example, and it is to be understood that embodiments of the present disclosure may be used in conjunction with various other structures. The specific materials and structures described are exemplary in nature, and other materials and structures may be used. Functional OLEDs may be obtained by combining the various layers described in different ways, or the layers may be omitted entirely based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many of the examples provided herein describe the various layers as comprising a single material, it is understood that combinations of materials may be used, such as mixtures of hosts and dopants, or more generally, mixtures. Further, the layer may have various sub-layers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emissive layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an "organic layer" disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise multiple layers of different organic materials as described, for example, with respect to fig. 1 and 2.
Structures and materials not specifically described may also be used, such as oleds (pleds) comprising polymeric materials, such as disclosed in U.S. patent No. 5,247,190 to frand (Friend), et al, which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. The OLEDs may be stacked, for example, as described in U.S. patent No. 5,707,745 to forrister (Forrest) et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in fig. 1 and 2. For example, the substrate may include an angled reflective surface to improve out-coupling (out-coupling), such as a mesa structure as described in U.S. Pat. No. 6,091,195 to Foster et al, and/or a pit structure as described in U.S. Pat. No. 5,834,893 to Boolean (Bulovic) et al, which are incorporated by reference in their entirety.
Any of the layers of the various embodiments may be deposited by any suitable method, unless otherwise specified. For organic layers, preferred methods include thermal evaporation, ink jetting (as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, both incorporated by reference in their entirety), organic vapor deposition (OVPD) (as described in U.S. Pat. No. 6,337,102 to Foster et al, both incorporated by reference in their entirety), and deposition by Organic Vapor Jet Printing (OVJP) (as described in U.S. Pat. No. 7,431,968, incorporated by reference in its entirety). Other suitable deposition methods include spin coating and other solution-based processes. The solution-based process is preferably carried out in a nitrogen or inert atmosphere. For other layers, a preferred method includes thermal evaporation. Preferred patterning methods include deposition through a mask, cold welding (as described in U.S. Pat. nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entirety), and patterning associated with some of the deposition methods such as inkjet and Organic Vapor Jet Printing (OVJP). Other methods may also be used. The material to be deposited may be modified to make it compatible with a particular deposition process. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3 to 20 carbons is a preferred range. A material with an asymmetric structure may have better solution processibility than a material with a symmetric structure because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.
Devices fabricated according to embodiments of the present disclosure may further optionally include a barrier layer. One purpose of the barrier layer is to protect the electrodes and organic layers from damage by exposure to hazardous substances in the environment including moisture, vapor, and/or gas. The barrier layer may be deposited on, under or beside the substrate, electrode, or on any other part of the device, including the edge. The barrier layer may comprise a single layer or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase and compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic compound or an organic compound or both. Preferred barrier layers comprise a mixture of polymeric and non-polymeric materials as described in U.S. patent No. 7,968,146, PCT patent application nos. PCT/US2007/023098 and PCT/US2009/042829, which are incorporated herein by reference in their entirety. To be considered a "mixture," the aforementioned polymeric and non-polymeric materials that make up the barrier layer should be deposited under the same reaction conditions and/or simultaneously. The weight ratio of polymeric material to non-polymeric material may be in the range of 95:5 to 5: 95. The polymeric material and the non-polymeric material may be produced from the same precursor material. In one example, the mixture of polymeric material and non-polymeric material consists essentially of polymeric silicon and inorganic silicon.
Devices manufactured according to embodiments of the present disclosure may be incorporated into a wide variety of electronic component modules (or units), which may be incorporated into a wide variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices (e.g., discrete light source devices or lighting panels), etc., which may be utilized by end-user product manufacturers. The electronics module may optionally include drive electronics and/or a power source. Devices manufactured in accordance with embodiments of the present disclosure may be incorporated into a wide variety of consumer products having one or more electronic component modules (or units) incorporated therein. A consumer product comprising an OLED comprising a compound of the present disclosure in an organic layer in the OLED is disclosed. The consumer product shall include any kind of product comprising one or more light sources and/or one or more of some type of visual display. Some examples of such consumer products include flat panel displays, curved displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, rollable displays, foldable displays, stretchable displays, laser printers, telephones, cellular telephones, tablet computers, tablet phones, Personal Digital Assistants (PDAs), wearable devices, laptop computers, digital cameras, video cameras, viewfinders, microdisplays (displays less than 2 inches diagonal), 3-D displays, virtual reality or augmented reality displays, vehicles, video walls containing multiple displays tiled together, theater or stadium screens, phototherapy devices, and signs. Various control mechanisms may be used to control devices made in accordance with the present disclosure, including passive matrices and active matrices. Many of the devices are intended to be used in a temperature range that is comfortable for humans, such as 18 ℃ to 30 ℃, and more preferably at room temperature (20-25 ℃), but can be used outside this temperature range (e.g., -40 ℃ to +80 ℃).
More details regarding OLEDs and the definitions described above can be found in U.S. patent No. 7,279,704, which is incorporated herein by reference in its entirety.
The materials and structures described herein may be applied to devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices such as organic transistors may employ the materials and structures.
In some embodiments, the OLED has one or more features selected from the group consisting of: flexible, rollable, foldable, stretchable, and bendable. In some embodiments, the OLED is transparent or translucent. In some embodiments, the OLED further comprises a layer comprising carbon nanotubes.
In some embodiments, the OLED further comprises a layer comprising a delayed fluorescence emitter. In some embodiments, the OLED comprises an RGB pixel arrangement or a white plus color filter pixel arrangement. In some embodiments, the OLED is a mobile device, a handheld device, or a wearable device. In some embodiments, the OLED is a display panel having a diagonal of less than 10 inches or an area of less than 50 square inches. In some embodiments, the OLED is a display panel having a diagonal of at least 10 inches or an area of at least 50 square inches. In some embodiments, the OLED is a lighting panel.
In some embodiments, the compound may be an emissive dopant. In some embodiments, the compounds may produce emission via phosphorescence, fluorescence, thermally activated delayed fluorescence (i.e., TADF, also known as E-type delayed fluorescence, see, e.g., U.S. application No. 15/700,352, which is incorporated herein by reference in its entirety), triplet-triplet annihilation, or a combination of these processes. In some embodiments, the emissive dopant may be a racemic mixture, or may be enriched in one enantiomer. In some embodiments, the compounds may be homoleptic (each ligand is the same). In some embodiments, the compounds may be compounded (at least one ligand being different from the others). In some embodiments, when there is more than one ligand that coordinates to the metal, the ligands may all be the same. In some other embodiments, at least one ligand is different from the other ligands. In some embodiments, each ligand may be different from each other. This is also true in embodiments where the ligand that coordinates to the metal can be linked to other ligands that coordinate to the metal to form a tridentate, tetradentate, pentadentate, or hexadentate ligand. Thus, where the coordinating ligands are linked together, in some embodiments all of the ligands may be the same, and in some other embodiments at least one of the linked ligands may be different from the other ligand(s).
In some embodiments, the compounds may be used as phosphorous photosensitizers in OLEDs, where one or more layers in the OLED contain an acceptor in the form of one or more fluorescent and/or delayed fluorescence emitters. In some embodiments, the compounds may be used as a component of an exciplex to be used as a sensitizer. As a phosphosensitizer, the compound must be capable of energy transfer to the acceptor and the acceptor will emit or further transfer energy to the final emitter. The receptor concentration may range from 0.001% to 100%. The acceptor may be in the same layer as the phosphorous sensitizer or in one or more different layers. In some embodiments, the receptor is a TADF emitter. In some embodiments, the acceptor is a fluorescent emitter. In some embodiments, the emission may be produced by any or all of the sensitizer, the receptor, and the final emitter.
According to another aspect, a formulation comprising a compound described herein is also disclosed.
The OLEDs disclosed herein can be incorporated into one or more of consumer products, electronic component modules, and lighting panels. The organic layer may be an emissive layer, and the compound may be an emissive dopant in some embodiments, while the compound may be a non-emissive dopant in other embodiments.
In yet another aspect of the present invention, a formulation comprising the novel compound disclosed herein is described. The formulation may include one or more of the components disclosed herein selected from the group consisting of: a solvent, a host, a hole injection material, a hole transport material, an electron blocking material, a hole blocking material, and an electron transport material.
The present disclosure encompasses any chemical structure comprising the novel compounds of the present disclosure or monovalent or multivalent variants thereof. In other words, the compounds of the present invention or monovalent or multivalent variants thereof may be part of a larger chemical structure. Such chemical structures may be selected from the group consisting of: monomers, polymers, macromolecules and supramolecules (also known as supramolecules). As used herein, "monovalent variant of a compound" refers to a moiety that is the same as a compound but where one hydrogen has been removed and replaced with a bond to the remainder of the chemical structure. As used herein, "multivalent variants of a compound" refers to moieties that are the same as a compound but where more than one hydrogen has been removed and replaced with one or more bonds to the rest of the chemical structure. In the case of supramolecules, the compounds of the invention may also be incorporated into supramolecular complexes without covalent bonds.
D. Combinations of the compounds of the present disclosure with other materials
Materials described herein as suitable for use in a particular layer in an organic light emitting device can be used in combination with a variety of other materials present in the device. For example, the emissive dopants disclosed herein may be used in conjunction with a wide variety of hosts, transport layers, barrier layers, implant layers, electrodes, and other layers that may be present. The materials described or referenced below are non-limiting examples of materials that can be used in combination with the compounds disclosed herein, and one of ordinary skill in the art can readily review the literature to identify other materials that can be used in combination.
a) Conductive dopant:
the charge transport layer may be doped with a conductivity dopant to substantially change its charge carrier density, which in turn will change its conductivity. The conductivity is increased by the generation of charge carriers in the host material and, depending on the type of dopant, a change in the Fermi level of the semiconductor can also be achieved. The hole transport layer may be doped with a p-type conductivity dopant and an n-type conductivity dopant is used in the electron transport layer.
Non-limiting examples of conductivity dopants that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified below: EP01617493, EP01968131, EP2020694, EP2684932, US20050139810, US20070160905, US20090167167, US2010288362, WO06081780, WO2009003455, WO2009008277, WO2009011327, WO2014009310, US2007252140, US2015060804, US20150123047 and US 2012146012.
Figure BDA0003067090940001231
Figure BDA0003067090940001241
b)HIL/HTL:
The hole injection/transport material used in the present disclosure is not particularly limited, and any compound may be used as long as the compound is generally used as the hole injection/transport material. Examples of materials include (but are not limited to): phthalocyanine or porphyrin derivatives; an aromatic amine derivative; indolocarbazole derivatives; a fluorocarbon-containing polymer; a polymer having a conductive dopant; conductive polymers such as PEDOT/PSS; self-assembling monomers derived from compounds such as phosphonic acids and silane derivatives; metal oxide derivatives, e.g. MoOx(ii) a p-type semiconducting organic compounds, such as 1,4,5,8,9, 12-hexaazatriphenylhexacyano-nitrile; a metal complex; and a crosslinkable compound.
Examples of aromatic amine derivatives for use in HILs or HTLs include, but are not limited to, the following general structures:
Figure BDA0003067090940001242
Ar1to Ar9Each of which is selected from: a group consisting of aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene,
Figure BDA0003067090940001243
Perylene and azulene; a group consisting of aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzoselenenopyridine, and selenenopyridine; and a group consisting of 2 to 10 cyclic structural units which are the same type or different types of groups selected from aromatic hydrocarbon ring groups and aromatic heterocyclic groups and are bonded to each other directly or via at least one of an oxygen atom, a nitrogen atom, a sulfur atom, a silicon atom, a phosphorus atom, a boron atom, a chain structural unit and an aliphatic ring group. Each Ar may be unsubstituted or may be substituted with a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, Ar1To Ar9Independently selected from the group consisting of:
Figure BDA0003067090940001251
wherein k is an integer from 1 to 20; x101To X108Is C (including CH) or N; z101Is NAr1O or S; ar (Ar)1Having the same groups as defined above.
Examples of metal complexes used in HILs or HTLs include, but are not limited to, the following general formulas:
Figure BDA0003067090940001252
wherein Met is a metal which may have an atomic weight greater than 40; (Y)101-Y102) Is a bidentate ligand, Y101And Y102Independently selected from C, N, O, P and S; l is101Is an ancillary ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal; and k' + k "is the maximum number of ligands that can be attached to the metal.
In one aspect, (Y)101-Y102) Is a 2-phenylpyridine derivative. In another aspect, (Y)101-Y102) Is a carbene ligand. In another aspect, Met is selected from Ir, Pt, Os and Zn. In another aspect, the metal complex has a structure comparable to Fc+A minimum oxidation potential in solution of less than about 0.6V for/Fc coupling.
Non-limiting examples of HIL and HTL materials that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified by the following: CN102702075, DE102012005215, EP01624500, EP0169861, EP01806334, EP01930964, EP01972613, EP01997799, EP02011790, EP02055700, EP02055701, EP1725079, EP2085382, EP2660300, EP650955, JP07-073529, JP2005112765, JP2007091, JP 2008021621687, JP2014-009196, KR 201188898, KR20130077473, TW 201139201139402, US06517957, US 2008220158242, US20030162053, US20050123751 751, US 20060282993, US 200602872 14579, US 201181874874, US20070278938, US 20080014014464 091091091, US20080106190, US 200907192605092385, US 12460352009071794392604335200356371798, WO 20120020120020135200353141563543544354435443544354435443544354435443544354435443544354435646, WO 200200352003520035563256325632563256325646, WO 20035200352003520035200435443544354435443544354435443544354435443544354435646, WO 200605646, WO 200605632563256325632563256325646, WO 2002002002002002002002002002002002002002004356325632563256325632563256325632563256325632563256325632563256325632567, WO 2004354435443435632563256325632563256325632563256325632563243544354434354435443544354435443544354435443544354435443541, WO 2002002002002002002002002002002002002002002002002002002002002002002002002002002004354435443544354435443544354435443544354435443544354435443544354435443544354435443544354435427, WO 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020060435443544354435443544354435427, WO 20020020020020020020020020020020020043544354435443544354435443544354435443544354435443544354435427, WO 20020020020020020020020020020020020020060435427, WO 20020020020020020020020060435427, WO 2002002002002006043544354435427, WO 2002002002002002002004354435427, WO 20043544354435427, WO 200200200200200604354435443544354435443544354435427, WO 200435443563256325632563256325632563256325632563256325632563256325632563256325632563256325632563256325632563256325632435427, WO 200200200200200200435427, WO 20020020020020020043200200200200200432002002002002004320043435427, WO 200435427, WO 20043200200200435427, WO 200200200435427, WO 200200200432004320020020020020043200435427, WO 200200200435427, WO 20043435427, WO 20020020020020020020020020020020020020020020020020043544320020020020020020043432004320043544354435427, WO 200200200200.
Figure BDA0003067090940001261
Figure BDA0003067090940001271
Figure BDA0003067090940001281
Figure BDA0003067090940001291
Figure BDA0003067090940001301
Figure BDA0003067090940001311
c)EBL:
An Electron Blocking Layer (EBL) may be used to reduce the number of electrons and/or excitons that leave the emissive layer. The presence of such a barrier layer in a device may result in substantially higher efficiency and/or longer lifetime compared to a similar device lacking a barrier layer. In addition, blocking layers can be used to limit the emission to the desired area of the OLED. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than the emitter closest to the EBL interface. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than one or more of the bodies closest to the EBL interface. In one aspect, the compound used in the EBL contains the same molecule or the same functional group as used in one of the hosts described below.
d) A main body:
the light-emitting layer of the organic EL device of the present disclosure preferably contains at least a metal complex as a light-emitting material, and may contain a host material using the metal complex as a dopant material. Examples of the host material are not particularly limited, and any metal complex or organic compound may be used as long as the triplet energy of the host is larger than that of the dopant. Any host material may be used with any dopant so long as the triplet criteria are met.
Examples of the metal complex used as the host preferably have the following general formula:
Figure BDA0003067090940001321
wherein Met is a metal; (Y)103-Y104) Is a bidentate ligand, Y103And Y104Independently selected from C, N, O, P and S; l is101Is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal; and k' + k "is the maximum number of ligands that can be attached to the metal.
In one aspect, the metal complex is:
Figure BDA0003067090940001322
wherein (O-N) is a bidentate ligand having a metal coordinated to the O and N atoms.
In another aspect, Met is selected from Ir and Pt. In another aspect, (Y)103-Y104) Is a carbene ligand.
In one aspect, the host compound contains at least one selected from the group consisting of: by e.g.Aromatic hydrocarbon cyclic compounds of the group consisting of: benzene, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, perylene,
Figure BDA0003067090940001323
Perylene and azulene; a group consisting of aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzoselenenopyridine, and selenenopyridine; and a group consisting of 2 to 10 cyclic structural units which are the same type or different types of groups selected from aromatic hydrocarbon ring groups and aromatic heterocyclic groups and are bonded to each other directly or via at least one of an oxygen atom, a nitrogen atom, a sulfur atom, a silicon atom, a phosphorus atom, a boron atom, a chain structural unit and an aliphatic ring group. Each option in each group may be unsubstituted or may be substituted with a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, the host compound contains at least one of the following groups in the molecule:
Figure BDA0003067090940001331
wherein R is101Selected from the group consisting of: hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof, and when it is aryl or heteroaryl, it has a similar definition to Ar mentioned above. k is an integer from 0 to 20 or from 1 to 20. X101To X108Independently selected from C (including CH) or N. Z101And Z102Independently selected from NR101O or S.
Non-limiting examples of host materials that can be used in OLEDs in combination with the materials disclosed herein are exemplified below, along with references disclosing those materials: EP2034538, EP2034538A, EP2757608, JP2007254297, KR20100079458, KR20120088644, KR20120129733, KR20130115564, TW201329200, US20030175553, US20050238919, US20060280965, US20090017330, US20090030202, US20090167162, US20090302743, US20090309488, US20100012931, US20100084966, US20100187984, US2010187984, US2012075273, US2012126221, US2013009543, US2013105787, US2013175519, US 001446, US 20148301503, US20140225088, US2014034914, US7154114, WO2001039234, WO 2004093203203203207, WO 2005014545454545452009020090455646, WO 2002012009020120090201902019072201200907220120020190722012002012002016072201200201200201200201607246, WO 20120020120020160722012002016072201200201200201607246, WO 200201200201200201200201200201200201200201200907220020120020120020120020120020120020120090729, WO 200201200201200201200201200201200201200201200201200201200201200201200201200201200201200201200201200200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200201200200200200201200201200200200200200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200201200201200200200200200200200200200200200200200200200200200201200201200200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200201200201200200200200200200201200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200,
Figure BDA0003067090940001341
Figure BDA0003067090940001351
Figure BDA0003067090940001361
Figure BDA0003067090940001371
Figure BDA0003067090940001381
Figure BDA0003067090940001391
e) other emitters:
one or more other emitter dopants may be used in combination with the compounds of the present invention. Examples of the other emitter dopant are not particularly limited, and any compound may be used as long as the compound is generally used as an emitter material. Examples of suitable emitter materials include, but are not limited to, compounds that can produce emission via phosphorescence, fluorescence, thermally activated delayed fluorescence (i.e., TADF, also known as E-type delayed fluorescence), triplet-triplet annihilation, or a combination of these processes.
Non-limiting examples of emitter materials that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified below: CN103694277, CN1696137, EB01238981, EP01239526, EP01961743, EP1239526, EP1244155, EP1642951, EP1647554, EP1841834, EP1841834B, EP2062907, EP2730583, JP 201207440263, JP4478555, KR1020090133652, KR20120032054, KR20130043460, TW201332980, US0669959, US 200100916520, US20010019782, US20020034656, US 20030068568526, US20030072964, US 2003013865657, US 200501787878788, US 20020020020020120044673, US2005123791, US 2006052449 449, US20060008670, US20060065890, US 601696, US 6016016016012006012016016310204659, US 2012002012002012002012002012000477817781979, WO 20020120020120020120020020020020020020004778177819748, US 20120020020004779, WO 200200200201200201200200200200200201200778177819748, US 20020120004779, US 20120020120020120020120020020120020020020004779, US 2002012002002002002002002002002002002002002002002002002002012000477819748, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 20020020020020020020020020020020020020020020020020020020120020120020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020120020120020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020120020120020020020020020020020020020020020020020020020020020020020020020020020020020020120020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020120020120020120020120043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, the No. 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200979, the No. 10,979, the No. 10,979, the No. 10, the No. 10,979, the No. 10,979, No. 10, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200, WO2012020327, WO2012163471, WO2013094620, WO2013107487, WO2013174471, WO2014007565, WO2014008982, WO2014023377, WO2014024131, WO2014031977, WO2014038456, WO 2014112450.
Figure BDA0003067090940001401
Figure BDA0003067090940001411
Figure BDA0003067090940001421
Figure BDA0003067090940001431
Figure BDA0003067090940001441
f)HBL:
Hole Blocking Layers (HBLs) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a barrier layer in a device may result in substantially higher efficiency and/or longer lifetime compared to a similar device lacking a barrier layer. In addition, blocking layers can be used to limit the emission to the desired area of the OLED. In some embodiments, the HBL material has a lower HOMO (farther from the vacuum level) and/or higher triplet energy than the emitter closest to the HBL interface. In some embodiments, the HBL material has a lower HOMO (farther from the vacuum level) and/or higher triplet energy than one or more of the hosts closest to the HBL interface.
In one aspect, the compound used in the HBL contains the same molecule or the same functional group as used for the host described above.
In another aspect, the compound used in HBL contains in the molecule at least one of the following groups:
Figure BDA0003067090940001451
wherein k is an integer from 1 to 20; l is101Is another ligand, and k' is an integer of 1 to 3.
g)ETL:
The Electron Transport Layer (ETL) may include a material capable of transporting electrons. The electron transport layer may be intrinsic (undoped) or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complex or organic compound may be used as long as it is generally used to transport electrons.
In one aspect, the compound used in the ETL contains in the molecule at least one of the following groups:
Figure BDA0003067090940001452
wherein R is101Selected from the group consisting of: hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof, which when aryl or heteroaryl has a similar definition to Ar described above. Ar (Ar)1To Ar3Have similar definitions as Ar mentioned above. k is an integer of 1 to 20. X101To X108Selected from C (including CH) or N.
In another aspect, the metal complex used in the ETL contains (but is not limited to) the following general formula:
Figure BDA0003067090940001453
wherein (O-N) or (N-N) is a bidentate ligand having a metal coordinated to atom O, N or N, N; l is101Is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal.
Non-limiting examples of ETL materials that can be used in an OLED in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified as follows: CN103508940, EP01602648, EP01734038, EP01956007, JP2004-022334, JP2005149918, JP2005-268199, KR0117693, KR20130108183, US20040036077, US20070104977, US2007018155, US20090101870, US20090115316, US20090140637, US 2009017959554, US2009218940, US2010108990, US2011156017, US2011210320, US2012193612, US2012214993, US 20140142014014925, US 201401492014927, US 2014028450284580, US 5666612, US 1508431, WO 200306093060979256, WO2007111263, WO2009148269, WO2010067894, WO2010072300, WO 201107070, WO 105373, WO 201303017, WO 201314545477, WO 2014545667, WO 201104376, WO2014104535, WO 2014535,
Figure BDA0003067090940001461
Figure BDA0003067090940001471
Figure BDA0003067090940001481
h) charge Generation Layer (CGL)
In tandem or stacked OLEDs, CGL plays a fundamental role in performance, consisting of an n-doped layer and a p-doped layer for injecting electrons and holes, respectively. Electrons and holes are supplied by the CGL and the electrodes. Electrons and holes consumed in the CGL are refilled by electrons and holes injected from the cathode and anode, respectively; subsequently, the bipolar current gradually reaches a steady state. Typical CGL materials include n and p conductivity dopants used in the transport layer.
In any of the above-mentioned compounds used in each layer of the OLED device, the hydrogen atoms may be partially or fully deuterated. Thus, any of the specifically listed substituents, such as (but not limited to) methyl, phenyl, pyridyl, and the like, can be in their non-deuterated, partially deuterated, and fully deuterated forms. Similarly, substituent classes (such as, but not limited to, alkyl, aryl, cycloalkyl, heteroaryl, etc.) can also be non-deuterated, partially deuterated, and fully deuterated forms thereof.
It should be understood that the various embodiments described herein are by way of example only and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without departing from the spirit of the invention. The invention as claimed may thus comprise variations of the specific examples and preferred embodiments described herein, as will be apparent to those skilled in the art. It should be understood that various theories as to why the invention works are not intended to be limiting.
E. Experimental data
Synthesis of 2- (Phenylmethoxy) -6-fluorobenzaldehyde (1)
Figure BDA0003067090940001482
2-fluoro-6-hydroxybenzaldehyde (25.0g, 178mmol), K under nitrogen2CO3A mixture of (74.0g, 535mmol) and benzyl bromide (32mL, 270mmol) in anhydrous MeCN (500mL) was stirred at Room Temperature (RT) for 18 h. The mixture was filtered, washed with EtOAc (2X 150mL), and the filtrate was concentrated in vacuo. Purification by chromatography gave 2- (benzyloxy) -6-fluorobenzaldehyde (1) (28.5g, 123mmol, 69% yield as a colourless liquid,>98% purity) which crystallizes upon standing.
Synthesis of 2- (2- (benzyloxy) -6-fluorophenyl) -1H-imidazole (2)
Figure BDA0003067090940001491
Adding ammonia (28 wt% in H)2In O) (100mL, 1.29mol) was added to glyoxal (40 wt.% in H)2In O) (75mL, 0.65mol) and 2- (benzyloxy) -6-fluorobenzaldehyde (1) (28.5g, 123mmol) in a stirred mixture of EtOH (350 mL). The reaction mixture was stirred at 50 ℃ for 19 hours. Additional glyoxal (40 wt.% in H) was added2O) (12.0mL, 262mmol) and the mixture stirred at 50 ℃ for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography in three equal batches to give a dark brown solid. This solid was wet-milled with TBME (300mL), filtered, washed with MTBE (2X 100mL) and dried in vacuo to give 2- (2- (benzyloxy) -6-fluorophenyl as a light brown powder) -1H-imidazole (2) (16.5g,60.3mmol, 49% yield,>98% purity).
Synthesis of 3- (benzyloxy) -2- (1H-imidazol-2-yl) -N-methylaniline (3)
Figure BDA0003067090940001492
A mixture of isopropyl magnesium chloride (2M in THF, 150mL, 300mmol) in diethylene glycol dimethyl ether (300mL) was cooled to 0 deg.C and methylamine (2M in THF, 120mL, 240mmol) was added over 5 minutes. The resulting mixture was stirred at 0 ℃ for 1 hour, followed by the addition of a suspension of 2- (2- (benzyloxy) -6-fluorophenyl) -1H-imidazole (2) (16.5g,60.3mmol) in diethylene glycol dimethyl ether (300mL) over 20 minutes. The resulting mixture was heated to 110 ℃ and stirred for 22 hours. The mixture was poured into saturated NH4In Cl (aq) (600mL), diluted with EtOAc (200mL) and sonicated for 2 min. The layers were separated and the aqueous phase was extracted with EtOAc (3X 300 mL). The combined organic extracts were washed with brine (400mL) over MgSO4Dried, filtered and concentrated in vacuo. Purification by column chromatography gave 3- (benzyloxy) -2- (1H-imidazol-2-yl) -N-methylaniline (3) (11.4g, 36.7mmol, 61% yield, 90% purity) as a light yellow solid.
Synthesis of 2- (1H-imidazol-2-yl) -3- (methylamino) phenol (4)
Figure BDA0003067090940001501
A mixture of 3- (benzyloxy) -2- (1H-imidazol-2-yl) -N-methylaniline (3) (11.4g, 36.7mmol) and Pd (10% on C, wetted with 50% water, 1.9g, 0.69mmol) in EtOH (150mL) and THF (80mL) was stirred under hydrogen (2 bar) at room temperature in a steel reaction vessel for 2H. The mixture was filtered (GF/F glass microfiber pad) and concentrated in vacuo. Purification by column chromatography gave 2- (1H-imidazol-2-yl) -3- (methylamino) phenol (4) (5.46g, 28.3mmol, > 77% yield, > 98% purity) as a brown solid.
Synthesis of 5- (2, 6-diisopropylphenyl) -6-methyl-5, 6-dihydrobenzo [ e ] imidazo [1,2-c ] [1,3,2] diazaborbane-10-ol (5)
Figure BDA0003067090940001502
TMSCl (4.30mL, 33.6mmol) was added under nitrogen to a solution of potassium (2, 6-diisopropylphenyl) trifluoroborate (9.00g, 33.6mmol) in anhydrous THF (30 mL). The resulting mixture was stirred at room temperature for 1 hour [ solution A ].
In a separate flask, n-BuLi (2.5M in hexanes, 20mL, 50mmol) was added to a solution of 2- (1H-imidazol-2-yl) -3- (methylamino) phenol (4) (3.00g, 15.9mmol) in anhydrous THF (30mL) under nitrogen at-78 ℃. The resulting mixture was stirred at-78 ℃ for 1 hour [ solution B ].
Solution a was added to solution B over 10 minutes at-78 ℃. The mixture was warmed to room temperature and then stirred at 60 ℃ for 1 hour. The mixture was cooled to room temperature and saturated NH was used4Cl (aq) (60mL) and diluted with water (60 mL). The aqueous layer was extracted with EtOAc (120mL, 3X 60mL) and the combined organic extracts were washed with brine (120mL), MgSO4Dried, filtered and concentrated in vacuo. Purification by column chromatography gave the product as a white powder (4.6g,<98% purity). This material was wet-milled with TBME (20mL) and the solid was collected by filtration, washed with TBME (2X 5mL) and dried in vacuo to give 5- (2, 6-diisopropylphenyl) -6-methyl-5, 6-dihydrobenzo [ e ] as a white powder]Imidazo [1,2-c ]][1,3,2]Diazaborin-10-ol (5) (2.63g, 7.31mmol, 46% yield, 99.6% HPLC).
Synthesis of phosphorescent complexes:
Figure BDA0003067090940001511
will [ IrL2Cl]2(1 eq, 0.02M), (5) (2.2 eq) and K2CO3(10 eq.) the heterogeneous mixture in THF was stirred at 60 deg.C under nitrogen for two days. The solvent is removed in vacuo and passedThe crude residue was purified by column chromatography to give the product in 35-65% yield.
Table 1-photophysical properties of the compounds of the invention:
Figure BDA0003067090940001512
complexes Ir [ L ] of the inventionA1-(33)(2)(1)(1)][LB148]2、Ir[LA1-(33)(2)(1)(1)][LB28]2And Ir [ L ]A1-(33)(2)(1)(1)][LB540]2The photoluminescence spectra of (a) are shown in figures 3-5. Such as the complex Ir [ L ]A1-(33)(2)(1)(1)][LB148]2、Ir[LA1-(33)(2)(1)(1)][LB28]2And Ir [ L ]A1-(33)(2)(1)(1)][LB540]2The spectra of (a) show that the compounds of the invention advantageously pair with multiple emissive ligand classes in phosphorescent complexes. The compounds of the present invention support highly efficient emission in the visible spectral range and their easy metallation makes them attractive ligands, whereby photophysical, electroluminescent and physical properties can be tailored to best suit their intended application.
Device experiment
The device 1:
the OLEDs were grown on glass substrates pre-coated with an Indium Tin Oxide (ITO) layer having a sheet resistance of 15- Ω/sq. Prior to any organic layer deposition or coating, the substrate was degreased with a solvent and then treated with oxygen plasma at 50W for 1.5 minutes at 100 mtorr and with UV ozone for 5 minutes.
The apparatus in Table 1 was operated by thermal evaporation under high vacuum (<10-6Tray). The anode electrode is
Figure BDA0003067090940001521
Indium Tin Oxide (ITO). Starting from the ITO surface, an example device has organic layers consisting of, in order:
Figure BDA0003067090940001522
compound 1(HIL),
Figure BDA0003067090940001523
Compound 2(HTL),
Figure BDA0003067090940001524
Compound 3(EBL),
Figure BDA0003067090940001525
Doped with a percentage of emitters 4(EML),
Figure BDA0003067090940001526
A compound of (5) (BL),
Figure BDA0003067090940001527
Compound 6(ETL),
Figure BDA0003067090940001528
Compound 7(EIL), followed by
Figure BDA0003067090940001529
Al (cathode). After fabrication, all devices were immediately encapsulated in a nitrogen glove box with epoxy-sealed glass lids ((R))<1ppm of H2O and O2) In (2) incorporating a moisture absorbent inside the package. The doping percentages are by volume.
Figure BDA00030670909400015210
Figure BDA0003067090940001531
Table 2.
Figure BDA0003067090940001532
The device 2:
the OLEDs were grown on glass substrates pre-coated with an Indium Tin Oxide (ITO) layer having a sheet resistance of 15- Ω/sq. Prior to any organic layer deposition or coating, the substrate was degreased with a solvent and then treated with oxygen plasma at 50W for 1.5 minutes at 100 mtorr and with UV ozone for 5 minutes.
The apparatus in Table 2 was operated by thermal evaporation under high vacuum (C:)<10-6Tray). The anode electrode is
Figure BDA0003067090940001533
Indium Tin Oxide (ITO). Starting from the ITO surface, an example device has organic layers consisting of, in order:
Figure BDA0003067090940001534
compound 1(HIL),
Figure BDA0003067090940001535
Compound 2(HTL),
Figure BDA0003067090940001536
Compound 3(EBL),
Figure BDA0003067090940001537
With a compound 9 (35%) and a percentage of the emitter-doped compound 8(EML),
Figure BDA0003067090940001538
With a compound 7(ETL) doped with a compound 10 (35%)
Figure BDA0003067090940001539
Compound 7(EIL), followed by
Figure BDA00030670909400015310
Al (cathode). After fabrication, all devices were immediately encapsulated in a nitrogen glove box with epoxy-sealed glass lids ((R))<1ppm of H2O and O2) In (2) incorporating a moisture absorbent inside the package. The doping percentages are by volume.
Figure BDA0003067090940001541
Table 3.
Figure BDA0003067090940001551
Ir[LA1-(33)(2)(1)(1)][LB148]2And Ir [ L ]A1-(33)(2)(1)(1)][LB28]2The electroluminescent device data also support the benefits of using the compounds of the present invention in phosphorescent materials. Not only maintains electroluminescent lifetime when standardized to the compounds of the invention, but also Ir [ L ]A1-(33)(2)(1)(1)][LB148]2The improvement in the case of (2.7 times). And although the spectral behavior between the compounds of the invention and the comparative compounds is comparable, the operating voltage is reduced by up to 15%, making the ligands of the invention effective tools in the design and manufacture of high efficiency, long lifetime OLED devices.
TABLE 4 theoretical calculation
Figure BDA0003067090940001552
Figure BDA0003067090940001561
Figure BDA0003067090940001571
Figure BDA0003067090940001581
Figure BDA0003067090940001591
Table 4 shows the calculated triplet energies, HOMO and LUMO of several compounds of the invention. Geometric optimization calculations were performed within the Gaussian (Gaussian)09 software package using the B3LYP hybridization functional and the CEP-31G basis set including the effective nuclear potential. The compounds exhibit a wide range of possible T's from deep blue to near infrared1Energy, which is required for full color displays.
It is understood that the correlation calculations obtained for these compounds using the DFT functional groups and basis groups identified herein are theoretical. The computational combination protocol used herein (e.g., gaussian with CEP-31G basis set) relies on the following assumptions: the electronic effects are additive and therefore can be extrapolated to the Complete Basis Set (CBS) limit using a larger basis set. However, when the objective of the study is to understand the HOMO, LUMO, S of a series of structurally related compounds1、T1The additive effect is expected to be similar when the bond dissociation energy, etc. varies. Thus, while the absolute error using B3LYP may be significant compared to other calculation methods, HOMO, LUMO, S calculated using the B3LYP protocol are expected1、T1And the relative difference between the bond-dissociation energy values reproduced the experiment fairly well. See, e.g., flood et al, material chemistry (chem. mater.)2016,28, 5791-. Furthermore, with respect to iridium or platinum complexes suitable for use in the OLED field, the data obtained from the DFT calculation is closely related to actual experimental data. See tawasie et al, journal of materials chemistry (j. mater. chem.)2012,22,6419-29,6422 (table 3) (showing DFT calculations closely related to actual data for various emission complexes); morelalo (Morello), g.r., journal of molecular modeling (j.mol.model.)2017,23:174 (studying various sets of DFT functions and basis sets and concluding that the combination of B3LYP and CEP-31G is particularly accurate for emissive complexes).

Claims (20)

1. A compound comprising a ligand L of formula IA
Figure FDA0003067090930000011
Wherein:
Z1、Z2、Z3、Z4、Z5and Z6Each of which is independently C or N;
k is selected from the group consisting of: a direct bond, O and S;
when K is O or S, then Z6Is C;
each of ring a1 and ring a2 is independently a 5-or 6-membered carbocyclic or heterocyclic ring, or a polycyclic fused ring system comprising more than one 5-or 6-membered carbocyclic or heterocyclic ring;
RAand RBEach of which is independently mono-substituted, up to a maximum of allowed substitutions, or no substitution;
the ligand LACoordinating to metal M by two indicated dashed lines;
m is selected from the group consisting of: ir, Os, Ru, Rh, Pt, Pd, Cu, Ag, Au, Be, Mg, Al, Ca, Ti, Mn, Co, Zn, Ga, Ge and Zr;
m is coordinated to at least one other ligand;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands;
L1is an organic linking group;
when M is selected from the group consisting of Ru, Os, and Ir, then K is O or S;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is a direct bond, then M forms at least one bond with oxygen or sulfur; and is
When M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is O or S, then L1Selected from the group consisting of: -CR ═ N-, -CR 'R "-, -NR' BR '-, -CR' R" O-, -CR 'R "S-, -CR' ═ CR" O-, -CR '═ CR "S-, -CR' ═ CR 'NR-, -CR' ═ CR" CR ″2-, -C (═ N-) -, -C (═ CR-) -, and formula II
Figure FDA0003067090930000021
The structure of (1);
ring A3 is a 5-or 6-membered carbocyclic ringOr a heterocycle with which Z is contained7And Z8Together form a system of 18 pi electrons;
Z7and Z8Each of which is independently C or N;
each RA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; and is
Any two adjacent RA、RB、RCR, R' and R "may be joined or fused together to form a ring.
2. The compound of claim 1, wherein each RA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof;
wherein Z3Selected from the group consisting of N and carbene carbon; and is
Z6Is C and K is O or S; or Z6Is N and K is a direct bond.
3. The compound of claim 1, wherein ring a1 is selected from the group consisting of: imidazoles, benzimidazoles, imidazole-based carbenes, benzimidazole-based carbenes, pyrimidines, pyrazoles, and pyridines; or ring a2 is selected from the group consisting of: benzene, pyridine, carbazole, benzimidazole, benzothiophene, dibenzothiophene, benzofuran, dibenzofuran, dibenzofluorene, naphthalene, tetrahydronaphthalene, phenoxazine, 9, 10-dihydroacridine, anthracene, and phenanthrene.
4. The compound of claim 1, wherein M is selected from the group consisting of Ru, Os, and Ir, and K is O or S.
5. The compound of claim 1, wherein the organic linking group L1Selected from the group consisting of: -X-, -X-X' -, -XL=XL' -and-XL=XL'-X-;
Wherein X and X' are each independently selected from the group consisting of: BR ', NR ', PR ', O, S, Se, C-O, S-O, SO2CR 'R', SiR 'R' and GeR 'R'; and is
XLAnd XL'Each independently selected from the group consisting of N and CR'.
6. The compound of any one of claims 1 to 5, wherein the organic linking group L1Having the formula II
Figure FDA0003067090930000031
Wherein ring a3 is a 5 or 6 membered ring.
7. The compound of any one of claims 1-5, wherein formula II is selected from the group consisting of:
Figure FDA0003067090930000032
wherein R isCSelected from the group consisting of:
Figure FDA0003067090930000033
Figure FDA0003067090930000041
Figure FDA0003067090930000051
8. the compound of claim 1, wherein M is selected from the group consisting of: pt, Pd, Cu, Ag or Au, and K is a direct bond, wherein the organic linking group L1Selected from the group consisting of: -X-, -X-X' -, -XL=XL' -and-XL=XL'-X-,
Wherein X and X' are each independently selected from the group consisting of: BR ', NR ', PR ', O, S, Se, C-O, S-O, SO2CR 'R', SiR 'R' and GeR 'R'; and is
XLAnd XL'are each independently selected from the group consisting of N and CR'.
9. The compound of claim 1, wherein M is selected from the group consisting of: pt, Pd, Cu, Ag or Au, and K is S or O, wherein L1Selected from the group consisting of: -CR ═ N-, -CR ' R "-, -NR ' BR ' -, -CR ' R" O-and-CR ' R "S-.
10. The compound of claim 1, wherein the ligand LASelected from the group consisting of:
Figure FDA0003067090930000052
Figure FDA0003067090930000061
Figure FDA0003067090930000071
Figure FDA0003067090930000081
Figure FDA0003067090930000091
Figure FDA0003067090930000101
wherein Q may be present or absent, and when present, is a first linking group; and wherein each R isC、R1、R2、R3And R4Independently hydrogen or a substituent selected from the group consisting of the general substituents defined herein.
11. The compound of claim 1, wherein the compound is of formula M (L)A)p(LB)q(LC)rWherein L isBAnd LCEach is a bidentate ligand; and wherein p is 1,2 or 3; q is 0, 1 or 2; r is 0, 1 or 2; and is
p + q + r is the oxidation state of the metal M.
12. The compound of claim 11, wherein LBAnd LCEach independently selected from the group consisting of:
Figure FDA0003067090930000111
Figure FDA0003067090930000121
wherein:
t is selected from the group consisting of: B. al, Ga and In;
Y1to Y13Each of which is independently selected from the group consisting of carbon and nitrogen;
y' is selected from the group consisting of: BR (BR)e、NRe、PRe、O、S、Se、C=O、S=O、SO2、CReRf、SiReRfAnd GeReRf
ReAnd RfMay be fused or joined to form a ring;
each Ra、Rb、RcAnd RdIndependently represent zero substitution, mono substitution, or up to the maximum allowed number of substitutions for its associated ring;
Ra1、Rb1、Rc1、Rd1、Ra、Rb、Rc、Rd、Reand RfEach of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, halo, alkyl, cycloalkyl, heteroalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; general substituents as defined herein; and is
Any two adjacent Ra、Rb、Rc、Rd、ReAnd RfMay be fused or joined to form a ring or to form a multidentate ligand.
13. The compound of claim 10, wherein when said compound is of formula Ir (L)A)3When L isAIs selected from the group consisting of LA,specAnd the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))3To Ir (L)A71-(R86))3A group of compounds;
when the compound has the formula Ir (L)A)(LBk)2When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); k is an integer from 1 to 540; and the compound is selected from the group consisting of Ir: (A), (B), (C) and C)LA1-(R1)(R1)(R1)(R1))(LB1)2To Ir (L)A71-(R86))(LB540)2A group of compounds;
when the compound has the formula Ir (L)Ai-m)2(LBk) When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); k is an integer from 1 to 540; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LB1) To Ir (L)A71-(R86))2(LB540) A group of compounds;
when the compound has the formula Ir (L)Ai-m)2(LCj-I) When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); j is an integer from 1 to 1416; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LC1-I) To Ir (L)A71-(R86))(LC1416-I) A group of compounds; and is
When the compound has the formula Ir (L)Ai-m)2(LCj-II) When L isAIs selected from the group consisting of LA,specThe group consisting of the structures of (a); j is an integer from 1 to 1416; and the compound is selected from the group consisting of Ir (L)A1-(R1)(R1)(R1)(R1))2(LC1-II) To Ir (L)A71-(R86))(LC1416-II) A group of compounds;
wherein each LB1To LB540Has the following structure:
Figure FDA0003067090930000141
Figure FDA0003067090930000151
Figure FDA0003067090930000161
Figure FDA0003067090930000171
Figure FDA0003067090930000181
Figure FDA0003067090930000191
Figure FDA0003067090930000201
Figure FDA0003067090930000211
Figure FDA0003067090930000221
Figure FDA0003067090930000231
Figure FDA0003067090930000241
Figure FDA0003067090930000251
Figure FDA0003067090930000261
Figure FDA0003067090930000271
Figure FDA0003067090930000281
Figure FDA0003067090930000291
Figure FDA0003067090930000301
Figure FDA0003067090930000311
Figure FDA0003067090930000321
Figure FDA0003067090930000331
Figure FDA0003067090930000341
Figure FDA0003067090930000351
Figure FDA0003067090930000361
Figure FDA0003067090930000371
wherein each LCj-IHas a formula based on
Figure FDA0003067090930000372
The structure of (1); and is
Each LCj-IIHas a formula based on
Figure FDA0003067090930000373
In respect of L, whereinCj-IAnd LCj-IIEach L inCj,R201And R202Each independently defined as follows:
Figure FDA0003067090930000381
Figure FDA0003067090930000391
Figure FDA0003067090930000401
Figure FDA0003067090930000411
Figure FDA0003067090930000421
Figure FDA0003067090930000431
Figure FDA0003067090930000441
Figure FDA0003067090930000451
Figure FDA0003067090930000461
Figure FDA0003067090930000471
Figure FDA0003067090930000481
Figure FDA0003067090930000491
Figure FDA0003067090930000501
wherein R isD1To RD246Has the following structure:
Figure FDA0003067090930000502
Figure FDA0003067090930000511
Figure FDA0003067090930000521
Figure FDA0003067090930000531
Figure FDA0003067090930000541
14. the compound of claim 11, wherein the compound is of formula II:
Figure FDA0003067090930000542
wherein:
M1is Pd or Pt;
rings E and F are each independently a 5-or 6-membered carbocyclic or heterocyclic ring;
z and Z' are each independently C or N;
K1and K2Each independently selected from the group consisting of: a direct bond, O and S, wherein K1And K2At least one of which is a direct bond;
L1is an organic linking group;
L2、L3and L4Each independently selected from the group consisting of: single bond, absent bond, O, S, CR 'R', SiR 'R', BR 'and NR', where L2、L3And L4Is present;
X3and X4Each independently is C or N;
REand RFEach independently represents zero substitution, mono substitution, or up to the maximum permissible substitution for its associated ring;
R'、R”、REand RFEach of which is independently hydrogen or a substituent selected from the group consisting of:
deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof; and is
Any two adjacent RA、RB、R、R'、R”、REAnd RFMay be joined or fused together to form a ring.
15. The compound of claim 14, wherein both Ring E and Ring F are 6-membered aromatic rings,
wherein ring F is a 5-or 6-membered heteroaromatic ring,
wherein L is1Selected from the group consisting of: o, CR 'R' and formula II
Figure FDA0003067090930000551
Is of structure (1), and
wherein L is2Is a direct bond or NR'.
16. The compound of claim 14, wherein the compound is selected from the group consisting of:
Figure FDA0003067090930000552
Figure FDA0003067090930000561
Figure FDA0003067090930000571
wherein:
L1aselected from the group of: -CR ═ N-, -CR 'R' -, -NR 'BR-, -CR' R 'O-, -CR' R 'S-, -CR ═ CR' O-、-CR'=CR"S-、-CR'=CR"NR-、-CR'=CR"CR2-, -C (═ CR-) -, and-C (═ N-) -;
L1bselected from the group of: -CR ═ N-, -CR2-、-CR=CR'-、-CR'R"CR'R"-、-NR'BR'-、-CR'R"O-、-CR'R"S-、-CR'=CR"O-、-CR'=CR"S-、-CR'=CR"NR-、-CR'=CR"CR2-, -C (-CR-) -, -C (-N-) -, and formula II
Figure FDA0003067090930000572
The structure of (1);
RYeach selected from the group consisting of: alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl, and combinations thereof;
each RGIndependently hydrogen or a substituent selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof; and any two RA、RB、RE、RF、RG、RYR, R' and R "may be joined together to form a ring;
wherein:
L1aselected from the group of: -CR ═ N-, -CR 'R "-, -NR' BR-, -CR 'R" O-, -CR' R "S-, -CR '═ CR" O-, -CR' ═ CR "S-, -CR '═ CR" NR-, -CR' ═ CR "CR ″2-, -C (═ CR-) -, and-C (═ N-) -;
L1bselected from the group of: -CR ═ N-, -CR2-、-CR=CR'-、-CR'R"CR'R"-、-NR'BR'-、-CR'R"O-、-CR'R"S-、-CR'=CR"O-、-CR'=CR"S-、-CR'=CR"NR-、-CR'=CR"CR2-, -C (═ CR-) -, and-C (═ N-) -.
17. An Organic Light Emitting Device (OLED), comprising:
an anode;
a cathode; and
an organic layer disposed between the anode and the cathode, wherein the organic layer comprises an organic material having the formulaLigand L of IAThe compound of (1):
Figure FDA0003067090930000581
wherein:
Z1、Z2、Z3、Z4、Z5and Z6Each of which is independently C or N;
k is selected from the group consisting of: a direct bond, O and S;
when K is O or S, then Z6Is C;
each of ring a1 and ring a2 is independently a 5-or 6-membered carbocyclic or heterocyclic ring, or a polycyclic fused ring system comprising more than one 5-or 6-membered carbocyclic or heterocyclic ring;
RAand RBEach of which is independently mono-substituted, up to a maximum of allowed substitutions, or no substitution;
the ligand LACoordinating to metal M by two indicated dashed lines;
m is selected from the group consisting of: ir, Os, Ru, Rh, Pt, Pd, Cu, Ag, Au, Be, Mg, Al, Ca, Ti, Mn, Co, Zn, Ga, Ge and Zr;
m is coordinated to at least one other ligand;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands;
L1is an organic linking group;
when M is selected from the group consisting of Ru, Os, and Ir, then K is O or S;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is a direct bond, then M forms at least one bond with oxygen or sulfur; and is
When M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is O or S, then L1Selected from the group consisting of: -CR ═ N-, -CR 'R "-, -NR' BR '-, -CR' R" O-, -CR 'R "S-, -CR' ═ CR" O-, -CR '═ CR "S-, -CR' ═ CR 'NR-, -CR' ═ CR" CR ″2-, -C (═ N-) -, -C (═ CR-) -, and formula II
Figure FDA0003067090930000591
The structure of (1);
ring A3 is a 5-or 6-membered carbocyclic or heterocyclic ring which is substituted with a group containing Z7And Z8Together form a system of 18 pi electrons;
Z7and Z8Each of which is independently C or N;
each RA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; and is
Any two adjacent RA、RB、RCR, R' and R "may be joined or fused together to form a ring.
18. The OLED of claim 17, wherein the organic layer further comprises a host, wherein host comprises at least one chemical moiety selected from the group consisting of: triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5, 9-dioxa-13 b-boranaphtho [3,2,1-de ] anthracene, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, and aza- (5, 9-dioxa-13 b-boranaphtho [3,2,1-de ] anthracene).
19. The OLED of claim 18 wherein the host is selected from the group consisting of:
Figure FDA0003067090930000601
Figure FDA0003067090930000611
Figure FDA0003067090930000612
and
combinations thereof.
20. A consumer product comprising an organic light emitting device, OLED, the OLED comprising:
an anode;
a cathode; and
an organic layer disposed between the anode and the cathode, wherein the organic layer contains a ligand L comprising formula IAThe compound of (1):
Figure FDA0003067090930000621
wherein:
Z1、Z2、Z3、Z4、Z5and Z6Each of which is independently C or N;
k is selected from the group consisting of: a direct bond, O and S;
when K is O or S, then Z6Is C;
each of ring a1 and ring a2 is independently a 5-or 6-membered carbocyclic or heterocyclic ring, or a polycyclic fused ring system comprising more than one 5-or 6-membered carbocyclic or heterocyclic ring;
RAand RBEach of which is independently mono-substituted, up to a maximum of allowed substitutions, or no substitution;
the ligand LACoordinating to metal M by two indicated dashed lines;
m is selected from the group consisting of: ir, Os, Ru, Rh, Pt, Pd, Cu, Ag, Au, Be, Mg, Al, Ca, Ti, Mn, Co, Zn, Ga, Ge and Zr;
m is coordinated to at least one other ligand;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands;
L1is an organic linking group;
when M is selected from the group consisting of Ru, Os, and Ir, then K is O or S;
when M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is a direct bond, then M forms at least one bond with oxygen or sulfur; and is
When M is selected from the group consisting of Pt, Pd, Cu, Ag and Au, and K is O or S, then L1Selected from the group consisting of: -CR ═ N-, -CR 'R "-, -NR' BR '-, -CR' R" O-, -CR 'R "S-, -CR' ═ CR" O-, -CR '═ CR "S-, -CR' ═ CR 'NR-, -CR' ═ CR" CR ″2-, -C (═ N-) -, -C (═ CR-) -, and formula II
Figure FDA0003067090930000622
The structure of (1);
ring A3 is a 5-or 6-membered carbocyclic or heterocyclic ring which is substituted with a group containing Z7And Z8Together form a system of 18 pi electrons;
Z7and Z8Each of which is independently C or N;
each RA、RB、RCR, R', R "are independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; and is
Any two adjacent RA、RB、RCR, R' and R "may be joined or fused together to form a ring.
CN202110529720.7A 2020-05-14 2021-05-14 Organic electroluminescent material and device Pending CN113666968A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063024566P 2020-05-14 2020-05-14
US63/024,566 2020-05-14
US202163155914P 2021-03-03 2021-03-03
US63/155,914 2021-03-03
US17/316,895 US20210380617A1 (en) 2020-05-14 2021-05-11 Organic electroluminescent materials and devices
US17/316,895 2021-05-11

Publications (1)

Publication Number Publication Date
CN113666968A true CN113666968A (en) 2021-11-19

Family

ID=78538129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110529720.7A Pending CN113666968A (en) 2020-05-14 2021-05-14 Organic electroluminescent material and device

Country Status (2)

Country Link
KR (1) KR20210142080A (en)
CN (1) CN113666968A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150026932A (en) * 2013-08-30 2015-03-11 유니버시티 오브 써던 캘리포니아 Organic electroluminescent materials and devices
US20170309838A1 (en) * 2016-04-22 2017-10-26 Universal Display Corporation Organic electroluminescent materials and devices
KR20190052504A (en) * 2017-11-08 2019-05-16 롬엔드하스전자재료코리아유한회사 Organic electroluminescent compound and organic electroluminescent device comprising the same
CN110028527A (en) * 2018-01-11 2019-07-19 环球展览公司 Electroluminescent organic material and device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150026932A (en) * 2013-08-30 2015-03-11 유니버시티 오브 써던 캘리포니아 Organic electroluminescent materials and devices
US20170309838A1 (en) * 2016-04-22 2017-10-26 Universal Display Corporation Organic electroluminescent materials and devices
KR20190052504A (en) * 2017-11-08 2019-05-16 롬엔드하스전자재료코리아유한회사 Organic electroluminescent compound and organic electroluminescent device comprising the same
CN110028527A (en) * 2018-01-11 2019-07-19 环球展览公司 Electroluminescent organic material and device

Also Published As

Publication number Publication date
KR20210142080A (en) 2021-11-24

Similar Documents

Publication Publication Date Title
CN113354687A (en) Organic electroluminescent material and device
KR20220124107A (en) Organic electroluminescent materials and devices
CN113717230A (en) Organic electroluminescent material and device
CN115073527A (en) Organic electroluminescent material and device
CN114230613A (en) Organic electroluminescent material and device
CN114524851A (en) Organic electroluminescent material and device
CN117447523A (en) Organic electroluminescent material and device
CN116425801A (en) Organic electroluminescent material and device
CN115536706A (en) Organic electroluminescent material and device
CN116003471A (en) Organic electroluminescent material and device
CN114957337A (en) Organic electroluminescent material and device
CN114853815A (en) Organic electroluminescent material and device
CN114349793A (en) Organic electroluminescent material and device
KR20220044670A (en) Organic electroluminescent materials and devices
CN115703811A (en) Organic electroluminescent material and device
CN114057799A (en) Organic electroluminescent material and device
CN114380866A (en) Organic electroluminescent material and device
CN113248544A (en) Organic electroluminescent material and device
CN112279874A (en) Organic electroluminescent material and device
CN113666968A (en) Organic electroluminescent material and device
CN115197277A (en) Organic electroluminescent material and device
CN115260247A (en) Organic electroluminescent material and device
CN115197278A (en) Organic electroluminescent material and device
CN115028664A (en) Organic electroluminescent material and device
CN115960143A (en) Organic electroluminescent material and device

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination